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Abstract 
 
Clinical observations report a higher propensity to develop Parkinson’s disease (PD) in 
amphetamine users. 3,4-Methylenedioxymethamphetamine (MDMA) is an amphetamine-related 
drug which may have neuroinflammatory and neurotoxic effects. The present study was aimed at 
evaluating in mice whether administration of MDMA during adolescence might influence 
neurotoxicity towards dopaminergic neurons and neuroinflammatory effects of 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP), a toxin known to induce PD in humans, in motor, 
limbic and cortical areas, and consequently affects cognitive performance. 
Mice received MDMA (10 mg/kg, twice a day/a week) for 9 weeks, followed by MPTP (20 
mg/kg × 4 administrations), starting 2 weeks after MDMA discontinuation. Activation of 
astroglia and microglia by GFAP and CD11b immunohistochemistry in motor areas, as 
substantia nigra compacta (SNc) and striatum, limbic and cortical areas, as hippocampus and 
medial prefrontal cortex (mPFC), was assessed. Degeneration of dopaminergic neurons by 
tyrosine hydroxylase (TH) immunohistochemistry in SNc and striatum was also evaluated. 
Neurochemical evaluations were paired with assessment of cognitive performance by means of 
the novel object recognition (NOR) and spontaneous alternation in a Y-maze tests. 
MPTP administration to MDMA-pretreated mice elicited a stronger increase in CD11b and 
GFAP levels in motor, limbic and cortical areas, and a stronger decrease of TH-positive neurons 
and fibers in motor areas, compared with either substance administered alone. Furthermore, 
NOR performance in the same group was lower, compared with mice that received either 
substance alone.  
Results demonstrate that MDMA administration during adolescence influence negatively MPTP 
effects on motor, limbic and cortical areas and result in cognitive impairment. 
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Introduction 
 
1. MDMA 
3,4-Methylenedioxymethamphetamine (MDMA), otherwise called “Ecstasy” (Figure 1), is a 
ring-substituted drug structurally correlated to the psychostimulant compounds as amphetamine, 
mescalin, 3,4-methylenedioxyamphetamine (MDA) and also to monoamine neurotransmitters. 
MDMA is a member of the larger group of ring-substituted phenylethylamines, and is 
characterized by a N-methyl group and a methylenedioxy ring on the third and fourth carbon of 
the phenyl ring, respectively. 
 
                 
 (A) Amphetamine      (B) Mescaline 
 
 
(C) MDA 3,4-Methylendioxyamphetamine  (D) MDMA 3,4-Methylendioxymethamphetamine 
 
Figure 1. Chemical structures of (A) amphetamine, (B) mescaline, (C) MDA and (D) MDMA. 
 
MDMA was first synthesized and patented by Köllisch at the German pharmaceutical company 
Merck in Darmstadt around 1912 and, at that time, it was not tested pharmacologically because it 
was regarded only as in a new synthetic procedure for haemostatic substances (Freudenmann et 
al. 2006). Moreover, MDMA was not mentioned in the Merck archive files for the next 15 years. 
In 1927, a Merck chemist, Oberlin, noted that the structure of MDMA was similar to that of 
ephetonine and adrenaline, and performed the first proven pharmacological test comparing the 
effects of MDMA with those of ephetonine. In 1952, another Merck chemist, van Schoor, 
conducted a simple toxicological experiment documented only by a short note in his personal 
laboratory book. In 1973, the first study was published in the literature that mentioned MDMA, 
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based upon toxicological research conducted in five animal species, including the mouse, in the 
early 1950s by the Army's Chemical Center (Hardman et al. 1973). The next phase of research 
on MDMA commenced when Alexander Shulgin appeared on the stage. According to Shulgin’s 
autobiography and to interviews, he synthesized and tested the effects of more than two hundred 
potentially psychoactive substances, including MDMA, often by taking these substances himself, 
and/or administering them to a close circle of collaborators. In 1990, Shulgin wrote a 
comprehensive “history of MDMA”, where it is reported that MDMA was first introduced into 
clinical practice on the West Coast of the United States in 1976, and was used by 
psychotherapists on the East Coast shortly after. Later, he specified that in 1977 he had 
introduced MDMA to Leo Zeff, a retired psychologist in Oakland, CA, who was so impressed by 
the effects of MDMA that he abandoned retirement and start to introduce MDMA to many 
psychotherapists across the United States (Benzenhöfer and Passie 2010). Meanwhile, in 1977, 
the UK classified MDMA as a class A schedule 1 drug, thus prohibiting to possess, sell, or give 
away the substance. In the USA, since the early 1980s, MDMA became popular in the streets as 
a recreational drug, and as a “fun drug” that was “good to dance”. In 1985, the American agency 
DEA classified MDMA as a Schedule 1 drug, due to its high abuse potential, lack of clinical 
applications, lack of certified safety for use under medical supervision, and suspects that it could 
be neurotoxic. The fame MDMA acquired in the USA soon spread across the Atlantic. Globally, 
the Europe remains the main center of MDMA production, although its relative importance 
appears to be declining, as MDMA manufacture has spread to other parts of the world in recent 
years, notably to USA and east and southeast Asia (European Monitoring Centre for Drugs and 
Drug Addiction –EMCDDA-, 2007). 
MDMA is almost exclusively sold and consumed orally in the form of tablets (rarely capsules), 
which frequently contain smart symbols (logos) and are colored, in order to capture the 
consumers’ attention. The amount of MDMA contained in the tables sold as “ecstasy” greatly 
varies from batch to batch (even among those tablets with the same logo), both between and 
within countries. Between 2008 and 2010, a change has occurred in the content of illicit drug 
tablets in Europe, from a situation where most of the tablets analysed contained MDMA (60–70 
mg of MDMA) or another ecstasy-like substance (MDA; 3,4-methylenedioxyethylamphetamine; 
paramethoxyamphetamine; 2,5-dimethoxy-4-bromoamphetamine; 4-methylthioamphetamine) as 
the only psychoactive substance, to one where the contents are more heterogeneous, and 
MDMA-like substances are often present in traces, or absent. This shift was most pronounced in 
2009, when only three countries reported that MDMA-like substances accounted for a large 
proportion of the content of the tablets analyzed. However, recent data indicate a rise in the 
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amount of MDMA contained in tablets. In 2011, average values ranging from 43 mg (Denmark) 
to 113 mg (Turkey) of MDMA per tablet were reported across Europe; moreover, the number of 
countries reporting a predominance of tablets containing MDMA-like substances has increased 
to eleven (EMCDDA, Table PPP-9, Composition of illicit drug tablets, 2011). 
 
1.1 Pharmacokinetics 
MDMA, similar to other amphetamine-related drugs, is a weak base (pKa = 9.9) with a low 
molecular weight, a low protein binding and a high volume of distribution (Capela et al. 2009). 
Moreover, MDMA is highly lipid soluble: this means that it is able to easily cross the blood brain 
barrier (BBB) and enter the brain without significant delay. 
Numerous studies have indicated that MDMA is well absorbed by the oral route, and reaches its 
maximum concentration after 1.5-3 hours from its intake, with a plasma half-life around 6-7 
hours (de la Torre et al. 2004).  
In both humans and rodents, MDMA is metabolized chiefly by the liver (de la Torre et al. 2004). 
In humans, the major metabolic pathway of MDMA is O-demethylation catalyzed by the hepatic 
cytochrome P450 (CYP) 2D6 (CYP2D6), which leads to the generation of 3,4-
dihydroxymethamphetamine (HHMA). MDMA is also a mechanism-based inhibitor of CYP2D6, 
a phenomenon that is associated with a decrease in the amount of effective enzyme (O’Mathùna 
et al. 2008). HHMA is further O-methylated by catechol-O-methyl transferase (COMT), 
generating 4-hydroxy-3-methoxymethamphetamine (HMMA) (de la Torre et al. 2004). In rats, 
N-demethylation to MDA predominates (de la Torre et al. 2004). MDA is further metabolized to 
the catechol intermediate, 3,4-dihydroxyamphetamine (HHA) and finally O-methylated to 4-
hydroxy-3-methoxyamphetamine (HMA). HHA and HHMA are the precursors of neurotoxic 
species. 
The metabolism of MDMA in experimental animals is qualitatively similar as for its major 
metabolic reactions in most animal species, even though quantitative differences exist. In 
rodents, the conversion to MDA is the main metabolic pathway of MDMA, but sex and strain 
differences in drug disposition exist, which have been attributed to the polymorphism of CYP 
isoenzymes (Koenig et al. 2005). In mice acutely administered with high doses of MDMA, the 
ratio between the parent compound and its metabolites is significantly higher than in rats, in both 
the plasma and the brain. However, this species difference largely disappeared when low doses 
of MDMA were tested in mice (Mueller et al. 2013). 
With regard to the clearance of MDMA in humans, about 80% of the drug is transformed 
metabolically through the liver, and the remaining 20% is excreted unaltered in urine in a dose-
independent fashion (Capela et al. 2009). It is quite difficult to make direct comparisons between 
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pharmacokinetics results obtained in humans and the few pharmacokinetics results from animal 
studies, since large mammals tend to dispose drugs at a lower rate than small mammals. In spite 
of that, it has been published that the clearance of MDMA and its metabolites was significantly 
faster in the mouse compared with the rat (Mueller et al. 2013). 
 
1.2 Pharmacology and toxicology 
Preclinical data gathered from research performed in laboratory animals, indicate that the 
systemic administration of MDMA affects the functions of both peripheral and central nervous 
system (CNS), mainly by acting on monoaminergic systems. Thus, initial studies showed that 
MDMA and its main metabolite, MDA, stimulate the efflux of 5-hydroxytryptamine (5-HT) (de 
la Torre et al. 2004) and dopamine (DA) from preloaded synaptosomes (Johnson et al. 1986; 
Schmidt et al. 1987). Subsequent reports have demonstrated that MDMA binds all the three 
presynaptic monoamine transporters with differences between species, exhibiting, in rodents, the 
highest affinity for the 5-hydroxytryptamine transporter (SERT), whilst the affinities for the 
noradrenaline (NET) and dopamine (DAT) transporters are lower (Rudnick and Wall 1992; 
Steele et al. 1987). MDMA also enhances the release of acetylcholine both in vitro in striatal 
slices and in vivo in prefrontal cortex (PFC) and striatum of rats, an effect that appears to derive 
from the activation of serotonergic, dopaminergic and/or histaminergic receptors (Gudelsky and 
Yamamoto 2008). At variance with data obtained in studies concerned with rodent transporters, it 
has been reported that, in humans, MDMA displays higher affinity for NET and lower, but 
similar, affinities for SERT and DAT (Verrico et al. 2007). 
Once translocated to the cytoplasm, MDMA increases the extracellular levels of 5-HT, DA and 
noradrenaline (NA) in multiple brain regions (Gudelsky and Yamamoto 2008). MDMA causes 
the dissipation of the proton gradient between the vesicles and the cytosol that is necessary for 
the proper functioning of the vesicular monoamine transporter (VMAT2), also inhibiting VMAT2-
mediated influx and proper storage of 5-HT in the terminal (Rudnick and Wall 1992). This event 
is boosted by the block of reuptake on presynaptic terminals, and by the inhibition of the 
monoamine oxidase (MAO) type B (Leonardi and Azmitia 1994). MDMA also blocks the 
activity of tryptophan hydroxylase (TPH, the rate-limiting enzyme in the synthesis of 5-HT), an 
effect that occurs as soon as fifteen min after MDMA intake, and persists for up to two weeks 
(Schmidt and Taylor 1987). Furthermore, MDMA causes a global increase in extracellular 5-HT 
throughout the brain regions bearing raphe afferents (Rudnick and Wall 1992). 
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Figure 2. Mechanism of action of MDMA. (1) MDMA is a substrate of SERT by which enters 
inside the neuronal terminal; (2) once inside, MDMA produces an acute and rapide release of 5-
HT from the storage vesicles; (3) MDMA is able to inhibits TPH and (4) MAO type B enzymes, 
further increasing the levels of free cytoplasmatic 5-HT; (5) MDMA promotes a rapid release of 
intracellular 5-HT to the neuronal synapse via reversal of the SERT activity; (6) 5-HT acts as 
agonist on 5-HT2A receptors (Capela et al. 2009). 
 
1.2.1. Toxicology in humans 
The appeal of MDMA is due to its special profile of actions, which includes amphetamine-like 
stimulant effects, coupled with feelings of increased emotional sensitivity and closeness to 
others. Based on this, Nichols (1986) postulated that MDMA is member of a novel class of 
compounds, in that it possesses unique effects, which means that MDMA cannot be classified as 
either a hallucinogen or a psychostimulant. Nichols proposed the term ‘‘entactogen’’ to describe 
the effects of MDMA and related compounds. MDMA “high” period is characterized mainly by 
disinhibition in social relations, greater openness of spirit, better acceptance of others (empathy 
effects), increased esteem and self-confidence, feeling of euphoria, increased vigilance, 
improvement of mood, and abolition of fatigue.  
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However, not every MDMA experience is positive, since up to the 25% of users report having 
had at least one adverse reaction, with prevalence of unpleasant feelings and bodily sensations 
(Davison and Parrott 1997). However, the possibility exists that the positive effects of MDMA 
may subside with repeated use, as suggested by Peroutka et al. (1988). Peripheral adverse effects 
of MDMA in humans include cardiac arrhythmias, hypertension, hyperthermia, hyponatremia, 
liver complications, seizures, coma, and death (Schifano 2004). Hyperthermia is a very relevant 
clinical problem in MDMA users, since body temperature elevation produced by the drug may 
reach up to 43 °C (Capela et al. 2009), and around 85–90% of recreational MDMA users report 
an increase in body temperature and sweating, accompanied by dehydration (Davison and Parrott 
1997). The issue of MDMA-induced hyperthermia is complex, since the biological mechanisms 
involved in heat production and progression to hyperthermia after exposure to the drug are not 
clearly understood. It is conceivable that the administration of a large dose of MDMA evokes 5-
HT release that activates sufficient 5-HT1B and 5-HT2A receptors within vasculature (Gudelsky et 
al. 1986) to induce constriction, interfering with the normal thermoregulatory mechanisms of the 
body (Sprague et al. 2003). In this regard, it is worth to mention the study of Blessing and 
colleagues (2003) where it is demonstrated that clozapine and olanzapine, atypical antipsychotic 
agents that act as antagonists respectively at the 5-HT1A and 5-HT2 receptors, reverse severe and 
potentially fatal hyperthermia elicited by MDMA acute administration in rats and rabbits. 
Several reports in humans and in laboratory animals indicate that the rises in body temperature 
induced by MDMA are strictly influenced by the external environment (Carvalho et al. 2002; 
Huether et al. 1997), with an important factor for the toxicity of the drug being the social 
gathering (also called “aggregation toxicity”). Thus, the typical conditions encountered in 
“raves” and clubs parties, where the music is deafening, room temperatures are high due to 
crowding, and people usually assume few water and lots of alcohol are crucial to amplify 
MDMA-induced hyperthermia, and also all the other acute toxic effects of MDMA described 
above (Green et al. 2003).  
Another problem related to the MDMA use is the so-called “serotonin syndrome”, which is 
caused by drug-induced excess of intersinaptic 5-HT (Gillman 1999; Hall and Henry 2006; 
Huether et al. 1997). The symptoms include behavioral hyperactivity, mental confusion, 
agitation, hyperreflexia, hyperpyrexia, tachycardia, shivering, clonus, myoclonus, ocular 
oscillations, and tremor (Gillman 1999; Hall and Henry 2006; Huether et al. 1997). The 
“serotonin syndrome” is often conceptualized as an unusual, or atypical, severe adverse MDMA 
reaction. However, Gillman (1999) argued that this syndrome was neither rare nor idiosyncratic, 
but represented a continuum of responses from mild to severe. The mild “serotonin syndrome” 
14 
(which is limited to three symptoms from above list) generally requires no direct medical 
intervention. Stronger responses (including four or more symptoms) would often necessitate 
medical supervision, and while severe reactions (including most of the symptoms from the list) 
could prove fatal. Nevertheless, in the light of the widespread use of MDMA, fatal intoxications 
still remain rare events (EMCDDA, Annual report on the State of the Drugs Problem in Europe, 
2010). Exposure to MDMA could be regarded as a “chemical stressor” on the immune system, as 
it induces immunosuppression (Connor 2004; Connor et al. 2005), which may have a significant 
impact on the health of abusers. These effects may involve alterations of neutrophil 
phagocytosis, reduction of the production of inflammatory cytokines, suppression of the 
production of interferon γ (INT-γ), and reduction of the expression of MCH-II molecules at the 
level of neuronal dendrites and macrophages. Furthermore, MDMA reduces the number of 
circulating lymphocytes, especially of TCD4+, suppresses the proliferation of the T cell line, and 
diverts the production of cytokines by favouring the specialization of Th0 into Th2. The 
immunosuppressive effects of MDMA are likely not a result of a direct action of the substance 
on immune cells, but rather stem from the release of immunomodulatory endogenous substances 
(Boyle and Connor 2010). 
MDMA can also cause a series of neurobehavioural disturbances that can appear during the first 
few hours from drug intake, and include depression, mania, psychosis, panic attacks, irritability, 
hallucinations, insomnia, tiredness, fatigue, and paranoid ideas (Cole and Sumnall 2003; Davison 
and Parrott 1997; Hall and Henry 2006; McCann et al. 1996). Hallucinations and paranoia can 
persist for days, or even weeks, after the intake of MDMA. In addition, cases of potentially fatal 
neurological effects, such as subarachnoid and intracranial hemorrhage and thrombosis, have 
been reported in MDMA consumers (Green et al. 2003).  
In contrast to the acute effects described so far, the evaluation of the long term effects of 
MDMA, including neurotoxicity, is complex, and these effects should not be underestimated. 
Adverse neuropsychiatric effects have been described after chronic MDMA use and, most 
notably, some recreational MDMA users display cognitive deficits (Fox et al. 2001; Parrott and 
Lasky 1998) that become more marked in heavy drug users (Morgan 2000). 
The existence of cognitive dysfunctions contributes to support the evidence of neurotoxicity 
induced by MDMA in the human brain. Indeed, functional magnetic resonance imaging (fMRI) 
studies have demonstrated that MDMA may induce serotonergic toxicity in brain areas involved 
in the regulation of cognition, mood and memory, such as the hippocampus and the PFC. A 
recent fMRI investigation that involved heavy abstinent MDMA users showed a significantly 
greater spatial extent of activation than controls in both the primary and secondary visual cortex, 
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suggesting that MDMA use may be associated with a long-lasting increase in cortical 
excitability, possibly through the loss of 5-HT input to cortical and subcortical regions 
(Bauernfeind et al. 2011). Positron emission tomography (PET) studies reported significant 
reductions in SERT binding compared to control subjects (McCann et al. 1998). In another PET 
study, Reneman et al. (2001) found an indication that women who heavy abused MDMA might 
be more susceptible to neurotoxic effects on serotonergic neurons than men who were heavy 
MDMA users, and that MDMA-induced neurotoxic changes in several brain regions of women 
who formerly abused MDMA are reversible. 
Even though in humans the neurotoxicity of MDMA on the serotonergic system has been 
suggested by several studies on the one hand, on the other hand the effects of MDMA on 
dopaminergic neurons are less certain (Tai et al. 2011). In this regard, it is worth mentioning a 
recent study that analyzed the neurotoxicity of MDMA and its catechol metabolites, α-
methyldopamine (α-MeDA) and N-methyl-α-methyldopamine (N-Me-α-MeDA) in human 
dopaminergic SH-SY5Y cells. In this investigation, α-MeDA and N-Me-α-MeDA were found to 
be neurotoxic to SH-SY5Y cells, leading to caspase 3-independent cell death in a concentration- 
and time-dependent manner, whereas MDMA did not show a concentration and time-dependent 
induction of cell death (Ferreira et al. 2013). 
 
Abuse properties of drugs during adolescence 
It must be considered that an increased risk of developing drug abuse and drug-related problems 
is often associated with the age of the consumers (Hawkins et al. 1992). Adolescents are likely to 
participate at “raves” and clubs parties, and it is during adolescence that most drug use and abuse 
patterns are initiated. In both humans and experimental animals, adolescence is a critical period 
during development (Casey et al. 2000), which is generally associated with the acquisition of 
mature survival skills that allow independence from parental care. Novelty-seeking, a 
temperamental/behavioral trait that is typical of this age period, might substantially contribute to 
both psychological and psychobiological vulnerability. In the light of preclinical studies 
suggesting that the behavioral responses to psychostimulants are the result of neurobiological 
adaptations that occur primarily in the mesolimbic dopaminergic system (Pierce and Kumaresan 
2006), it is expected that exposure to MDMA during adolescence, as happen with other 
substances, would produce long-term changes in these systems that perpetuate in adulthood 
(Chambers et al. 2003; Morley-Fletcher et al. 2002; Sisk and Zehr 2005; Wahlstrom et al. 2009), 
and that the adverse peripheral reactions observed in adult would be more pronounced (Spear 
2000). 
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Regarding cognitive deficits, little is known of brain functional modifications of MDMA use 
during adolescence. In the study of Jacobsen and co-workers (2004), adolescent MDMA users 
displayed significant delays in reaction time during simple, selective and divided attention tasks 
and abnormal function of the left hippocampus during high working memory load. Moreover, the 
study of Weinborn and collaborators (2011) support a deficit in prospective memory functioning 
amongst MDMA young users (18–30 years) for longer (15 min) ongoing task delays, as 
compared with shorter (2 min) delays. 
 
1.2.2. Toxicology in experimental animals 
The most important acute effects of MDMA depend on several factors, such as the dose 
administered, the age at administration, the species, the environmental temperature, the thermal 
conductivity of the animal housing, and the hydration status. 
 
Non-human primates 
MDMA suppresses locomotor activity in non-human primates following both intramuscular 
(i.m.) (Von Huben et al. 2007) and oral (Crean et al. 2007) administration. Differently from what 
observed in rats, the environmental temperature seems not to affect MDMA-induced 
hyperthermia in non-human primates, as suggested by data in rhesus macaques administered 
with doses ranging between 0.56 and 2.4 mg/kg that displayed a similar degree of hyperthermia 
across a wide range of environmental conditions (18 °C to 30 °C) (Von Huben et al. 2007). 
Nevertheless, MDMA induces acute hyperthermia in unrestrained rhesus monkeys, an effect that 
is much more pronounced than in rats, mice, pigs, rabbits and humans. Maximum and average 
temperature in the four hours interval post-dosing was elevated by 0.7–0.9 °C after racemic 
MDMA and either enantiomer (Taffe et al. 2006). 
Non-human primates administered MDMA seem to be very susceptible towards the neurotoxic 
effects of this substance. A dose-dependent reduction in the 5-HT content in several brain areas 
has been observed in squirrel monkeys after the subcutaneous (s.c.) administration of MDMA at 
doses ranging between 2.5 and 5.0 mg/kg (Ricaurte et al. 1988a). In another study, MDMA was 
administered at the same doses, and significant decreases in cerebrospinal fluid (CSF) levels of 
5-hydroxyindoleacetic acid (5-HIAA) and brain 5-HT and 5-HIAA concentrations were observed 
(Insel et al. 1989). In addition, the long-lasting deficits characteristic of MDMA-induced 
neurotoxicity were evidenced by the fact that squirrel monkeys presented reduced serotonergic 
innervations and reduced 5-HT levels seven years following exposure to the drug. The route of 
drug administration also seems to affect the degree of 5-HT depletion, as oral administration has 
been reported to be less toxic than s.c. injection. It is noteworthy that repeated MDMA 
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administrations at a dose of 5 mg/kg have been reported to produce an 86% depletion of frontal 
cortex 5-HT when given s.c., compared with a 42% depletion elicited by the same dose given 
orally (Ricaurte et al. 1988b). Furthermore, since a single 5 mg/kg oral dose in non-human 
primates has been suggested to be equivalent to a 1.4 mg/kg dose in a 70 kg human, based on 
interspecies dose scaling, these data may indicate a possible risk of serotonergic damage in 
humans even after a single dose (Ricaurte et al. 1988b). 
There are few preclinical studies in non-human primates focused on MDMA ability to induce 
cognitive deficits. Nevertheless, Taffe and collaborators (2001) have demonstrated that rhesus 
monkeys, treated with a MDMA regimen able to induce a 50% reduction of  5-HIAA in CSF and 
persistent reductions of 5-HT content in several neocortical regions and hippocampus, and 
display overt deficits in a range of cognitive domains, like self-ordered spatial search, five-
choice reaction time task, progressive ratio responding, and bimanual motor skill task that do not 
persist when animals are retested few months later. 
 
Rodents 
Administration of MDMA has profound effects not only on the cardiovascular and 
neuroendocrine systems, but also on the thermoregulatory system and the basal metabolism of 
rats (Gordon et al. 1991). Several studies have reported that rats housed at room temperature 
conditions (20–24 °C) display an acute hyperthermic response following administration of 
MDMA (Colado et al. 1999; Dafters 1994; Mechan et al. 2002; O’Loinsigh et al. 2001). 
Exposing rats to higher ambient room temperature conditions results in rats having a higher 
hyperthermic response to MDMA, while exposure to lower ambient temperatures is associated 
with a hypothermic response to MDMA (Malberg and Seiden 1998). 
Another interesting point in MDMA toxicity is that MDMA tablets are often taken, in the “raves” 
and clubs parties, together with caffeinated beverages or with beverages contaminated with 
caffeine in varying amounts. Rat studies have shown that caffeine enhances hyperthermic and 
tachycardic responses induced by MDMA (Vanattou-Saïfoudine et al. 2010). 
There is considerable evidence that MDMA administration produces a major release of both 5-
HT and DA from their respective terminals in the forebrain (Johnson et al. 1986; Schmidt et al. 
1987), and that MDMA-induced hyperthermia may be associated with an increased 5-HT 
(Shankaran and Gudelsky 1999). Several studies have demonstrated that MDMA causes long-
term neurodegeneration in the rat brain, particularly in the neocortex, striatum, thalamus, 
hippocampus, septum, and amygdala, even though strain differences in this effect exist, with the 
Dark Agouti strain being more sensitive than other commonly used strains (Baumann et al. 2007; 
Colado et al. 1995; Logan et al. 1988). The terminal portions of axons have been shown to be 
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selectively vulnerable to MDMA-induced damage, as indicated by the reduced density of fine, 
arborized 5-HT axons and sparing of smooth, straight preterminal fibers (Molliver et al. 1990). A 
very relevant point in MDMA toxicity observed in rats is that this effect appeared particularly 
marked during adolescence. Thus, adolescent rats, repeatedly treated with MDMA at several 
time points, displayed a significantly reduced SERT-immunoreactive fibers density in the 
hippocampus, a deficit in the novel object-recognition task (NOR), an increased impulsivity in 
the elevated plus-maze, and a reduced sensitivity to a 5-HT1A agonist challenge (Meyer et al. 
2008). Paralleling to serotonergic fibers damage, other research groups displayed that astrocyte 
hypertrophy can occur as a result of neuronal injury after single or repeated MDMA treatment, 
and can lead to the enhanced expression of glial fibrillary acidic protein (GFAP) (Adori et al. 
2006; Aguirre at al. 1999), the major protein of astrocyte intermediate filaments. In addition, it 
has been shown that acute MDMA treatment induces learning deficits in rats. Adolescent 
Sprague–Dawley rats treated with MDMA displayed, five days after the last dose, an impairment 
in NOR and increased open arm exploration in the elevated plus maze (Piper and Meyer 2004). 
This suggests that MDMA exposure during the adolescence may influence cognitive and 
affective functioning in the absence of severe serotonergic damage (Piper and Meyer 2004). 
Similar to what observed in rats, MDMA administration produces a hyperthermic response in 
mice. The mice strain, the MDMA dose (Mann et al. 1997) and the housing conditions appear to 
influence the magnitude and features of the response detected. Fantegrossi and colleagues (2003) 
have demonstrated that racemic MDMA and the S(+)-MDMA enantiomer were approximately 
equipotent in terms of their lethal effects across singly housed mice or mice housed in crowded 
cages (twelve per cage), while the R(–)-MDMA enantiomer was approximately half as potent. 
MDMA lethality was reversed with the temperature decrease, as a cold environment significantly 
attenuated the lethal effects of racemic MDMA in singly housed mice, and completely abolished 
the lethal effects of racemic MDMA and S(+)-MDMA in mice housed in crowded cages. These 
effects could likely be explained by an inhibition of MDMA metabolism (Mueller et al. 2013).  
It is now well established that MDMA produces in mice a neurotoxic profile different from the 
serotonergic one observed in rats or non-human primates, eliciting a significant dopaminergic 
neurotoxicity (O’Callaghan and Miller 1994). The basis for the variations in the profile of 
MDMA neurotoxicity across different species is unknown, but it has recently been suggested that 
differences in MDMA disposition and CYP metabolism may play a key role (Green et al. 2012). 
Nevertheless, MDMA can elicit dopaminergic neurotoxicity depending on its dosage (Itzhak et 
al. 2003).  
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Several studies have described MDMA-induced cognitive deficits in mice, but very few is 
known about cognitive deficits elicited by MDMA in adolescent mice (Ros-Simò et al. 2013; 
Vidal-Infer et al. 2012), indicating that further investigations are necessary to clarify whether 
neurochemical deficits induced by MDMA during adolescence correlate with behavioral and 
cognitive abnormalities. 
 
1.2.3 Mechanisms involved in MDMA toxicology 
Even though a large number of studies have been carried out to address the mechanisms involved 
in MDMA-induced neurotoxicity, these remain to be fully elucidated. Several lines of evidence 
indicate that multiple mechanisms can be involved, and that these mechanisms may differ 
depending on the specific toxic effect considered. 
  
Hyperthermia 
Several in vivo studies indicate that hyperthermia plays an important role in MDMA-induced 
neurotoxicity. As mentioned above, MDMA toxicity to 5-HT terminals during hyperthermic and 
hypothermic conditions can be enhanced and attenuated, respectively. The mechanism by means 
of which MDMA interferes with the regulation of body temperature is not fully understood. A 
study by Mechan et al. (2002) has demonstrated that the temperature of the tail was unaltered in 
rats following a dose of MDMA that produced a significant rise in rectal temperature. Since 
vasodilation of tail vessels is a major mechanism by which rats lose temperature (Grant 1963) 
these results suggest that MDMA could interfere with heat loss mechanisms. In this regard, it is 
worth mentioning the work by Gordon et al. (1991) who examined modifications in 
thermoregulatory mechanisms by MDMA by measuring metabolic rate, evaporative water loss 
and rectal temperature of rats housed at 10°, 20° and 30 °C. MDMA was able to produce a 
temperature-dependent increase in the metabolic rate and evaporative water loss. Hyperthermia 
by itself is not able to decrease the striatal levels of DA in rodents (Granado et al. 2011), but 
might interact with other known mediators of MDMA neurotoxicity, such as increased glutamate 
(GLU) neurotransmission and ROS production. A role for GLU in this effect is suggested by 
results showing that rats treated with the neuroprotective NMDA receptor antagonists 
memantine, MK-801, or CGS 19755 displayed a significantly decreased hyperthermia in 
response to MDMA (Nisijima et al. 2012). Moreover, it is noteworthy that MDMA-induced 
hyperthermia is associated with an increase in the formation of ROS and reactive nitrogen 
species (RNS) in Hep G2 cells (da Silva et al. 2013). 
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ROS production and oxidative stress 
The hypothesis that substituted amphetamines may induce toxicity by inducing ROS production 
was proposed as early as 1989 by Stone and collaborators, after the observation that MDMA-
induced inactivation of TPH was reversed by sulfhydryl-reducing compounds. This hypothesis 
was later supported by the findings that the neurotoxic effects of MDMA can be attenuated by 
either ROS scavengers and antioxidants or the over-expression of antioxidant enzymes (Cadet et 
al. 1994 and 1995a; Jahanthi et al. 1999). 
Consistent evidence from several reports supports the idea that ROS are produced from four 
different pathways. 
The first takes into consideration that MDMA elicits DA release both in vitro and in vivo (Cadoni 
et al. 2005), which may undergo over auto-enzymatic oxidation, resulting in the production of 
ROS catalyzed by Fe+++ via the Fenton reaction, mainly hydroxyl radical (HO●), superoxide  
(O2-) and hydrogen peroxide (H2O2) (Siraki and O'Brien 2002), cytotoxic quinone (Stokes et al. 
1999), and reactive aldehyde intermediates, such as 3,4-dihydroxyphenylacetaldehyde (DOPAL) 
(Marchitti et al. 2007). The role of elevation in DA release in MDMA-induced neurotoxicity has 
been substantiated by studies showing that the blockade of DAT (Kanthasamy et al. 2002) 
protect against neuronal damage induced MDMA. 
The second pathway that lead to the production of ROS involve the GLU, that may contribute to 
MDMA-induced neurotoxic effets in three different ways. In the first, GLU activates N-methyl-
D-aspartic acid (NMDA) receptor, leading to the increase in intracellular Ca++ levels, an effect 
that causes the activation of a variety of proteases and kinases and results in the breakdown of 
cytoskeletal proteins and the formation of ROS (Sattler and Tymianski 2000 and 2001). The 
second occur via a Ca++-mediated activation of a synthase that produces nitric oxide (NO). 
Under physiological conditions, both the neuronal form of nitric oxide synthase (nNOS) and 
inducible form of nitric oxide synthase (iNOS), locateted in glial cells, produce significant 
amounts of NO, while levels of the HO● radical are kept in check by the abundance of 
superoxide dismutase (SOD). In pathological conditions, NO can either react with O2- to form 
peroxynitrite (ONOO−), or with Fe++ and Cu++ to generate ROS (Lafon-Cazal et al. 1993; Radi 
et al. 1991). The mechanism through which NO and ONOO− mediate the toxicity of substituted 
amphetamines is not completely understood, however, the inhibition of nNOS, and the decrease 
of ONOO− levels, attenuate MDMA-induced depletions in striatal 5-HT (Darvesh et al. 2005). 
Moreover, it has been suggested that NO and ONOO− may oxidaze tyrosine residues in proteins, 
producing nitro-tyrosyne (Stamler and Hausladen 1998). Moreover, as mentioned before, 
MDMA-induced hyperthermia may interact with GLU, contributing to the neurotoxic effect. 
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The third pathway involves the demethylated metabolites of MDMA, such as MDA, that can 
promote the generation of cytotoxic species, as ROS and quinone intermediates. 
The last mechanism involve the mitochondrial complex I. It has been demonstrated that MDMA 
administration determines the inhibition of mitochondrial complex I in the striatum of mouse, 
leading to ROS overproduction (Puerta et al. 2010) 
In addition to these four pathways, the 5-HT released from MDMA may reacts with ROS and 
RNS, leading to the formation of a 5-HT-toxic metabolite, tryptamine-4,5-dione (T-4,5-D), which 
rapidly conjugates with glutathione (GSH) and reacts with other –SH-containing groups (Wrona 
and Dryhurst 2001). The role of elevation in 5-HT release in MDMA-induced neurotoxicity has 
been substantied by the finding that blockade of 5-HT uptake by fluoxetine or citalopram 
facilitates the recovery of TPH activity following MDMA administration (Schmidt and Taylor 
1987). 
Taken together ROS, produced from the oxidation of DA, from GLU and from MDMA 
metabolites may contribute to mitochondria inactivation and oxidation of macromolecules such 
as lipids, DNA, and proteins, leading to neuronal death (Quinton and Yamamoto 2006).  
 
Neuroinflammation  
The role of neuroinflammation in the toxicity of amphetamine-related drugs is not as well 
defined as that of hyperthermia and oxidative stress; nevertheless, its importance in the toxicity 
of these drugs is highlighted by the fact that only neurotoxic amphetamines produce microglial 
activation (Thomas et al. 2004). 
Microglial cells are the immune cells of the CNS (Kim and de Vellis 2005). They respond to 
insult with a reaction known as “microglial activation”. Many molecules and conditions can 
trigger a transformation of resting (or surveying) microglia to activated (alerted or reactive) 
states, included MDMA. There are few preclinical studies that have investigated the mechanisms 
by which microglial activation may contribute to MDMA-induced neurotoxicity, and all of them 
suggest that an increase in the expression of cytokines, such as interleukin-1 beta (IL-1β), may 
promote neuroinflammation (Orio et al. 2004; O’Shea et al. 2005). Conversely, activation of 
microglial cells by MDMA seems not to depend on hyperthermia (Orio et al. 2004). 
Astroglial cells hold neurons in place, get nutrients to them, and digest pats of dead neurons. 
Moreover, astrocytes can generate chemical signals in order to communicate with neurons: once 
activated, the levels of Ca++ in the citoplasma of astocytes are increased, and gliotransmitters are 
released. Gliotransmitters are able to deliver their message in a process very similar to that used 
by neurotransmitters (Agulhon et al. 2012).  
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Activation of microglia and astroglia occurs at different stages, and, tipically, activated microglia 
secretes pro-inflammatory cytokines (Allan and Rothwell 2001), which promote astrocytic 
activation. Among the various cytokines, IL-1β is a pivotal mediator also in the neurotoxicity 
induced by activated astrocytes. IL-1β is fast expressed in these pathological conditions, and 
determines the up-regulation of other inflammatory cytokines, such as IL-6 and tumour necrosis 
factor alpha (TNF-α) (Johnstone et al. 1999; Merril and Benveniste 1996; Smith et al. 2012). 
MDMA administration to rodents elicits astrocytic hypertrophy in several brain areas, the 
hallmark of which is an enhanced expression of GFAP, that accompanies the rapid and persistent 
decline in DA and TH (O’Callaghan and Miller 1994; Granado et al. 2008a). Sharma and Ali 
(2008) have reported that MDMA administration induces the most massive activation of 
astrocytes, that is located in the edematous areas of the cortex, and that the magnitude and 
intensity of GFAP immunoreaction in the brain is more pronounced in mice than in rats. 
Several studies have reported a dual effect of MDMA, on both microglial and astroglial 
activation. A research from Granado and collaborators (2008a) suggested for the first time that 
MDMA administration induces in mice DA toxicity in SNc and striatum, paired with an increase 
in neuroinflammation, by showing that MDMA produces a significant decrease in the number of 
TH-positive neurons in the SNc, and in TH and DAT-immunoreactivity in the striatum. 
Moreover, a recent study from our laboratory has demonstrated that administration of MDMA to 
mice, elicits a significant stereoselective activation of CD11b and GFAP immunoreactivity in the 
striatum, nucleus accumbens, motor cortex, and SNc, and correlates with an increase in body 
temperature and motility (Frau et al. 2013). The glial response is further potentiated by the co-
administration of MDMA with caffeine (Khairnar et al. 2010).  
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Figure 3. Schematic diagram of the possible causative factors and consequences of MDMA 
toxicity. 
 
1.3 MDMA and Parkinson’s disease (PD) 
Parkinson's disease (PD) is a neurological disorder, characterized by the loss of dopaminergic 
neurons in the SNc (Hornykiewicz and Kish 1986). The etiology of the disease is unknown, but 
it is very likely that more than one factor, like genetic predisposition, oxidative stress, 
mitochondrial dysfunction, excitotoxicity, neuroinflammation and exposure to toxins, may play a 
role in the patology (Marsden and Olanow 1998). Over the years, several clinical reports have 
found a higher rate of amphetamine-related drug exposure during the young age in patients 
diagnosed with neurodegenerative diseases, such as PD, compared with general population 
(Callaghan et al. 2010; Christine et al. 2010; Parrott et al. 2004). This has led to the hypothesis 
that amphetamine consumption may be a causative factor of PD, although some criticism has 
been raised to these studies, as amphetamine consumers are often polidrug abusers (Brust 2010). 
The study carried out by Garwood et al. (2006) employed a telephone survey conducted on 
patients with neurodegenerative diseases, including PD, peripheral neuropathy, and amyotrophic 
lateral sclerosis, who abused amphetamine-like drugs. The results obtained have shown that 
prolonged exposure to these substances is statistically more frequent in patients with PD than in 
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patients suffering from other neurodegenerative diseases; moreover, exposure to amphetamine 
occurred long before diagnosis in a significant percentage of individuals.  
The causes of the dopaminergic cell loss in the SNc that underlies PD patients are not clear, but 
in the last decade solid evidence has linked it to intense neuroinflammation. PET studies 
revealed microglial activation in pons, basal ganglia including substantia nigra (SN), frontal and 
temporal cortical regions of individuals with PD, starting early in the disease process without 
significant longitudinal changes (Gerhard et al. 2006; McGeer et al. 1988; Ouchi et al. 2005). 
Further supporting a pathogenic role of neuroinflammation, post-mortem samples taken from PD 
patients have also shown infiltration of CD4+ and CD8+ T cells in the brain (Brochard et al. 
2009). However, despite the progress made so far, the fundamental question remains whether 
immune-associated mechanisms are the main cause of the progressive loss of dopaminergic 
neurons, or are rather a consequence of the dopaminergic neurons. 
Even though the typical symptoms of PD are motor (Fearnley and Lees 1991), non motor 
symptoms, including cognitive deficits, are increasingly being recognized in PD patients 
(Foltynie et al. 2004), and no studies have evaluated the influence of the exposure to exogenous 
substances (including amphetamine-related drugs) early in life on the onset of these symptoms. 
 
1.4 MDMA and the nigrostriatal system in humans and experimental animals 
The nigrostriatal system connects the SN to the striatum. It is one of the four DA pathways in the 
brain, and is usually more envisioned as involved in the production of movement, although fMRI 
and PET studies indicate that this pathway in the healthy modulates non-motor behavior and 
cognition (Cropley et al. 2006; Landau et al. 2009). 
Despite the continuously increasing number of studies that are focused on MDMA-induced 
toxicity in the mice nigrostriatal system, few studies have addressed this issue in humans (Tai et 
al. 2011). As mentioned before, MDMA mostly affects the dopaminergic system in mice, rather 
than the serotonergic system (O’Callaghan and Miller 1994). MDMA administration depletes DA 
and its metabolites in several brain regions, but in particular produces long-term degeneration of 
striatal DA nerve terminals (Brodkin et al. 1993; Colado et al. 2001; Izco et al. 2007). A 
significant contribute to the elucidation of the effects of MDMA in the nigrostriatal system of 
mice comes from a recent study by Granado and co-workers (2008a), which shows that not all 
the dopaminergic systems are affected, because they found no TH or DAT fiber loss in the NAc, 
indicating that the dopaminergic neurotoxicity of MDMA is selective for the nigrostriatal 
pathway. In a later study, the same group demonstrated that the decrease in TH levels expression 
in mice treated with MDMA is accompanied by a reduction in DAT, which is considered an 
important marker of functional dopaminergic nerve terminals, suggesting that MDMA does not 
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reduce TH synthesis, but rather damages dopaminergic terminals, with an effect that appears 
more pronounced in the striosomal compartment than in the matrix (Granado et al. 2008b). 
Remarkably, a similar pattern of striosomal damage in the striatum has been observed following 
the administration of dopaminergic neurotoxins such as 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) (Iravani et al. 2005), and confirms earlier studies which described 
dopaminergic terminal loss in the mouse striatum following MDMA administration (Fornai et al. 
2004). 
 
1.5 MDMA and the limbic system in humans and experimental animals  
The limbic system includes several brain areas such as the limbic cortex, hippocampus, 
parahippocampal gyrus, limbic midbrain areas, amygdala, anterior thalamic nuclei, fornix, 
column of fornix, mamillary body, septum pellucidum, habenular commisure, cingulate gyrus, 
and the olfactory bulbs. The hippocampus, which plays a prominent role in the consolidation of 
information from short-term memory to long-term memory and spatial navigation (Eichenbaum 
et al. 1996; Squire 1992), contains two main interlocking parts, where can be identified two 
major neuronal types: in the Cornu Ammonis the predominant neuronal type has a pyramidal 
morphology, whereas in the dentate gyrus, the predominant neuronal type is the granular cells. 
Moreover, in both the two areas, it has been identified tyrosine hydroxylase (TH)-labeled 
terminals and GABA-containing terminals (Bentivoglio and Morelli 2005; Milner and Bacon 
1989).  
As mentioned earlier, cognitive deficits are among the typical long-term effects observed in 
heavy MDMA users. These deficits depend on the effects of MDMA on the hippocampus, seem 
to be dose-related, and may vary according to complexity of the cognitive task. 
Fox and colleagues (2001) have demonstrated that both medium and high MDMA users display 
cognitive deficits that depend on drug dosage but are not related to the extent of drug use. 
Previous studies have also associated consumption of MDMA, considered as a whole, with 
cognitive problems (Bolla et al. 1998; Parrott and Laskey 1998), whilst other have shown that 
impaired cognitive performance may depend on both the amount of MDMA consumed per 
session and the duration of MDMA use (Morgan 1999). Moreover, Brown and collaborators 
(2010) have demonstrated that memory tasks with high complexity reveal more marked deficits 
in MDMA users than memory tasks with a low complexity. Finally, PET studies have displayed 
differences in the activation of the hippocampus between MDMA users and healthy controls 
during working memory tasks (Becker et al. 2013; Daumann 2004 and 2005; Moeller et al. 
2004).  
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Several studies have also described MDMA-induced learning and cognitive deficits in mice. 
Thus, acute and repeated pretreatment with MDMA modifies the acquisition and execution of an 
active avoidance task (Trigo et al. 2008). Moreover, repeated administration of MDMA at 
different doses is associated with deficits in the Morris water maze that persist even long after 
last MDMA administration (Busceti et al. 2008). Interestingly, the same doses of MDMA that 
induced spatial learning deficits in the Morris water maze were able to induce tau protein 
phosphorylation in the hippocampus, a biochemical hallmark of Alzheimer’s disease, 
frontotemporal dementia, and other chronic neurodegenerative disorders characterized by a 
progressive cognitive decline (Alonso et al. 2001; Goedert 1993).  
 
1.6 MDMA and the PFC in humans and experimental animals  
The ascending mesostriatal and mesocortical dopaminergic systems widely modulate the 
cognitive functions supported by the PFC (Dalley et al. 2004; Ragozzino et al. 1999), a brain 
area enriched with dopaminergic terminals (Bentivoglio and Morelli 2005), and the striatal 
structures associated with it (Passingham and Sakai 2004). Thus, a wealth of evidence collected 
in drug abusers and individuals affected by various diseases, including PD patients (Bowen and 
Davison 1975; Downes et al. 1989) indicates that an altered dopaminergic function is associated 
with some of the cognitive impairments typically seen after PFC damage (Manes et al. 2002; 
Rogers et al. 1999). Moreover, even though most of the dopaminergic afferents to the PFC arise 
from the ventral tegmental area, some of them originate in the central area of the SNc (Albanese 
et al. 1986; Maurice et al. 1999; Middleton and Strick 2002) which can be very relevant for the 
changes in cognitive function associated with PD. 
A PET study by McCann et al. (2008) showed that memory performance of recreational MDMA 
users was inversely associated with SERT binding levels, in the dorso-lateral PFC, orbitofrontal 
cortex, and parietal cortex. Moreover, a recent PET study has revealed glucose hypometabolism 
in the PFC and parietal cortex of chronic MDMA and other drugs users, which correlates with 
verbal learning and recall deficits (Bosch et al. 2013).  
Consistent with these data are findings in rodents showing that chronic administration of 
amphetamine-related drugs can induce enduring reductions in monoamine levels in the striatum 
and PFC, and that, under at least some schedules of administration, neurotoxic and 
neuroinflammatory effects can occur (Atkins et al. 2009; Ball and Slane 2012; Ramos et al. 
2005).  
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2. MPTP 
In the late 1970s, an analogue of the synthetic opioid meperidine (Demerol ®), with the chemical 
name of 1-methyl-4-phenyl-4-propionpiperidine (MPPP), and with an effect comparable to that 
induced by heroin, was discovered. A twenty-three years old graduate student, Barry Kidstone, 
set up a home laboratory to synthesize MPPP, but after four injections of what he thought to be 
MPPP, he experienced severe bradykinesia (Langston and Ballard 1983). Furthermore, similar to 
patients with idiopathic PD, he responded to treatment with L-3,4-dihydroxyphenylalanine (L-
DOPA) and developed the same complications associated with L-DOPA therapy, including motor 
fluctuations and dyskinesias (Langston and Ballard 1983). Investigations were then conducted  to 
clarify the etiology of his condition which found that MPPP was contaminated with MPTP, a 
byproduct of the synthetic reaction, which was later identified as the responsible of the 
degeneration of dopaminergic neurons in the SNc (Langston et al. 1983).  
After this first documented episode, others young drug addicts developed an idiopathic 
parkinsonian syndrome after intravenous (i.v.) self-administration of MPPP (Ballard et al. 1985).  
Since its discovery, MPTP has been widely used to create animal models of PD in a variety of 
species (Jakowec and Petzinger 2004; Kopin 1987; Kurosaki et al. 2004), though the most used 
species are currently the non-human primates and the mouse. Susceptibility to MPTP varies 
across species, strain and age of animals (Giovanni et al. 1994a and b). Non-human primates are 
the species most sensitive and rats the lowest sensitive to MPTP neurotoxicity, whereas mouse 
strains widely vary in their sensitivity to the toxin, with the C57BL/6J being the most susceptible 
(Hamre et al. 1999; Sedelis et al. 2000). MPTP neurotoxicity has been found to be strongly age-
dependent in all the species (Date et al. 1990; Irwin et al. 1992; Ovadia et al. 1995; Ricaurte et 
al. 1986). Rats have been generally not used for modeling PD with systemic MPTP 
administration like in other species, since the dosage required to induce a significant 
dopaminergic degeneration is associated with a high mortality rate (Giovanni et al. 1994a and b). 
However, stereotaxic injection of the toxic metabolite 1-methyl-4-phenylpyridinium (MPP+) has 
been used to model PD in rats (Heikkila et al. 1985a). 
 
2.1 Toxicology  
 
2.1.1 Toxicology in humans  
Administration of MPTP to humans and experimental animals causes the degeneration of 
dopaminergic neurons in SNc and the depletion of DA in striatum. The severity of MPTP-
induced lesion depends on the regimen and route of administration, and on the species 
considered. 
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With the exception of a single report (Ballard et al. 1985), all human cases of MPTP intoxication 
were caused by one, or few repeated administrations of the toxin (Langston 1987). A 
neuropathologic study of the brains of three MPTP-exposed addicts has revealed another 
important similarity with idiopathic PD (Langston et al. 1999), that is the loss of dopaminergic 
neurons restricted to the SNc, though not accompanied by Lewy bodies. The absence of Lewy 
bodies may be due to the young age at the onset of MPTP-induced parkinsonism, since age may 
be an important factor for development of the Lewy bodies (Gibb and Lees 1988). Moreover, 
PET studies using [18F]-DOPA have revealed that MPTP-intoxicated individuals display a 
severely reduced DA uptake similar to that of late-stage idiopathic PD (Calne et al. 1985; Snow 
et al. 2000; Vingerhoets et al. 1994). Finally, the depletion of nigral dopaminergic neurons was 
found to be consistently present together with gliosis and clustering of microglia around nerve 
cells (Langston et al. 1999). 
 
2.1.2 Toxicology in experimental animals 
 
Non-human primates 
Non-human primate models closely resemble the behavioral and neuroanatomical features of 
human PD and this species may be useful for exploring the neurological and pathological 
mechanisms of the disease (Fox and Brotchie 2010). Moreover, and similar to humans, non-
human primates are susceptible to doses of MPTP lower than those that cause a nigrostriatal 
lesion in other species (Johannessen et al. 1985). Similar to humans, PET studies in cynomolgus 
and rhesus monkeys treated with MPTP have revealed a severe reduction in DA uptake (Pate et 
al. 1993). Thus, Moratalla and co-workers (1992), have reported that MPTP treatment in squirrel 
monkeys induces a higher loss of dopaminergic uptake-site binding in the putamen than in the 
caudatus, especially posteriorly. Moreover, Iravani and collaborators (2005) showed that 
subacute MPTP treatement is associated with a greater damage in striosomes than in matrix 
within the caudate nucleus. Administration of MPTP to non-human primates causes several 
parkinsonian-like symptoms, including bradykinesia, postural instability, freezing, stooped 
posture, and rigidity (Porras et al. 2012). These symptoms may be also accompanied by 
cognitive impairment manifested in several tasks and reflecting a general impairment of 
attentional and executive functions (Decamp et al. 2004; Decamp and Schneider 2004 and 2006; 
Schneider and Kovelowski 1990; Schneider and Roeltgen 1993). Interestingly, MPTP-treated 
primates also suffer a dramatic disruption of sleep–wake architecture, with reduced sleep 
efficacy that persisted years after MPTP administration (Porras et al. 2012), reminiscent of what 
observed in idiopatic PD patients (Comella 2008). Similar to idiopatic PD patients, MPTP-
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lesioned non-human primates respond to anti-parkinsonian therapies such as L-DOPA and DA 
receptor agonists. The degree of clinical response to L-DOPA is dependent on the severity of the 
lesion and parkinsonian state.  
 
Mice 
To overcome the economic and moral limitations of experiments involving MPTP use in non-
human primates, a MPTP model has been developed in mice. The C57BL/6J strain, in particular, 
is very susceptible to MPTP neurotoxicity, making an excellent conventional preclinical model 
for PD. In general, MPTP is administered to mice in either an acute or subchronic regimen 
(Heikkila et al. 1984; Sonsalla and Heikkila 1986). In these models, MPTP can produce death of 
dopaminergic neurons in SNc by at least the 40% in C57BL/6J mice and significant depletions in 
the striatal level of DA and its metabolites, 3,4-dihydroxyphenylacetic acid (DOPAC) and 
homovanillic acid (HVA), along with a reduction in the striatal synaptosomal DA uptake 
(Ricaurte et al. 1986). However, if the survival time of mice is extended, the neurotoxic effects 
of MPTP may be reversible (Hallman et al. 1985). MPTP administration in mice induce a 
neuroinflammatory effect in the SNc, striatum (Czlonkowska et al. 1996; Kohutnicka et al. 1998; 
Kurkowska-Jastrzebska et al. 1999; Kurosaki et al. 2003), and hippocampus (Luellen et al. 
2003). Bradykinesia, akinesia, altered balance and other motor features can be observed in 
MPTP-treated mice through various behavioral analyses (Fleming et al. 2013; Sedelis et al. 
2001; Tillerson et al. 2002) although, despite the evidence of DA reductions, mice that receive 
MPTP acutely do not always exhibit motor dysfunctions or motor abnormalities (Heikkila et al. 
1989; Meredith and Rademacher 2011). Whole-body tremor and postural abnormalities also have 
been reported, but chiefly in the first day after lesioning (Sedelis et al. 2001). Cognitive deficits 
after MPTP exposure in mice parallel the findings in non-human primates, even though with a 
much less effect (Tanila et al. 1998). In general, all these behavioral alterations tend to be highly 
variable, with some mice developing severe deficits whereas others exhibit little or no behavioral 
changes (Sedelis et al. 2001). This variability may be due to a number of factors, including the 
dose of MPTP, the mouse strain, the test sensitivity, and the period elapsed between lesioning 
and evaluation, when recovery may occur. 
 
2.2 Pharmacological and toxicological mechanisms 
The mechanism of MPTP toxicity is quite similar among humans, non-human primates and 
mice. MPTP is a highly lipophilic protoxin which rapidly crosses the BBB after systemic 
administration. Subsequently, MPTP is bioactivated by MAO type B enzymes to the unstable 
intermediate 1-methyl-4-phenyl-2,3-dihydropyridium (MPDP+), exclusively in non-
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dopaminergic cells, especially in astrocytes (Ekblom et al. 1993). MPDP+ spontaneously 
oxidizes to MPP+ at least in vitro (Chiba et al. 1985; Fritz et al. 1985), whereas it is not clear if 
this reaction may occur in vivo. Another mechanism for MPDP+ oxidation to MPP+ involves 
HO● radicals (Castagnoli et al. 1985), which appears in line with the evidence showing that 
transgenic mice expressing high levels of superoxide dismutase are resistant to MPTP 
(Przedborski et al. 1992), and that dopaminergic neurons are very susceptible to the toxin. Once 
generated, MPP+ is released into the extracellular space by a mechanism that is still unknown. 
MPP+ is not able to enter dopaminergic neurons freely, and its uptake depends on active plasma 
membrane carrier systems, such as the DAT, for which MPP+ bears a high affinity (Chiba et al. 
1985; Heikkila et al. 1985b). Interestingly, DAT is an absolute requirement for MPTP-induced 
neurotoxicity, since this effect is abolished in transgenic mice lacking this transporter (Bezard et 
al. 1999; Gainetdinov et al. 1997). 
Once inside the cell, MPP+ can either be sequestered into synaptic vesicles via VMAT2 (Del 
Zompo et al. 1993; Wimalasena et al. 2008) or enter into the mitochondria where it interferes 
with the mitochondrial complex I (Mizuno et al. 1987; Richardson et al. 2007). Both of these 
steps have been implicated in processes that either protect or kill the dopaminergic neurons. Staal 
and co-workers (2000) have demonstrated that rat striatal vesicles have a higher density of 
VMAT2 and a greater ability to sequester MPP+, compared with those isolated from mice, thus 
justifying why rats are less sensitive to MPP+-induced toxicity. The primary reason for the 
neuroprotective effect of vesicular MPP+ sequestration is that less MPP+ can be accumulated into 
mitochondria, thus reducing mitochondrial damage.  
Regarding the metabolism of MPTP, three major specie-related differences have been identified: 
1) non-human primates, but not rodents, show a persistently high concentration of MPTP 
metabolites in the striatum, compared to other brain regions; 2) the rodent brain clears MPTP and 
its metabolites much more rapidly than what observed in non-human primates; 3) the 
predominant metabolite retained by the non-human primates brain is MPP+, while MPP+ cannot 
be detected in rodent brain for more than a few hours after injection (Johannessen et al. 1985). 
The presence of CYP2D6 in human and nonhuman primates and of the similar isoform CYP2D1 
in rat brain indicates that this subfamily of CYP enzymes may be responsible for MPTP 
metabolism (Herraiz et al. 2006; Mann and Tyndale 2010). The persistence of MPP+ in the non-
human primate brain may explain the heightened toxicity of MPTP in this species. The principal 
route of elimination of MPTP is through the urine (Lau et al. 1988). 
The ability to interfere with mitochondrial respiration at the level of complex I is a key 
mechanism in the toxic effects of MPP+ (Nicklas et al. 1985; Suzuki et al. 1990). Importantly, the 
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cytotoxic effects of MPP+ are more marked in cells that are particularly sensitive to a deficiency 
in aerobic energy metabolism, a condition that applies to dopaminergic neurons, which have 
been found to be more vulnerable to inhibition of oxidative phosphorylation than other types of 
neurons (Marey-Semper et al. 1993 and 1995). However, the alterations in energy metabolism 
and generation of ROS peak within hours from MPTP administration, long before the occurrence 
of overt neuronal damage (Jackson-Lewis et al. 1995). Therefore, these events appear not to be a 
primary cause of neuronal death, but to initiate a cascade of events that eventually kill 
dopaminergic neurons (Gibson et al. 2010; Serra et al. 2002). One controversial aspect is 
whether MPTP induces neuronal death via apoptosis or necrosis. Przedborski and Jackson-Lewis 
(1998) have proposed that subchronic administration of MPTP is most likely to cause apoptosis, 
whereas necrotic cell death would be triggered by acute dosing. In this regard, it has however to 
be definitively clarified if during neurodegenerative conditions, such as PD, neurons degenerate 
by apoptosis or necrosis (Anglade et al. 1997; Kösel et al. 1997). 
Further contributions to clarify the mechanisms of MPTP-mediated neurotoxicity apparently 
come from NO (Przedborski et al. 1996), the induction of GLU-mediated excitotoxicity, and the 
stimulation of neuroinflammation. Some studies have also suggested that MPP+ may act 
independently of inhibition of mitochondrial complex I (Choi et al. 2008; Gerlach et al. 1996).  
 
Decline in ATP production and increase in ROS levels 
As mentioned before, MPP+ blocks mitochondrial complex I (Nicklas et al. 1985; Suzuki et al. 
1990), leading to a decline in adenosine triphosphate (ATP) levels. There is evidence of a good 
correlation between MPP+ concentrations, decline in ATP synthesis and cell death in hepatoma 
cells (Sandy et al. 1988). Furthermore, MPP+ has been shown to affect complex III (Mizuno et 
al. 1988), which leads to an increased production of ROS, HO● and O2- in particular.  
In vitro experiments have shown that the interaction between MPP+ and the complex I may also 
induce the formation of ROS, and in particular HO● and O2- (Cleeter et al. 1992; Sriram et al. 
1997). Interestingly, investigations in humans have found a decrease in complex I activity in 
various diseases, including PD (Lin and Beal 2006; Mizuno et al. 1989). Thus, low activity of 
complex I may translate to increased production of ROS, a depletion of SOD, and eventually an 
increased oxidative stress within the DA neuron. This idea is supported by experiments showing 
that, as long as sufficient stores of SOD are present, mice are protected against the effects of 
MPTP (Klivenyi et al. 1998). Moreover, neuronal stress could arise from a perturbation of DA 
homeostasis, as MPTP-induced DA release from citoplasmatic vesicular storage may trigger the 
formation of oxidizing metabolites and by-products, such as DA quinones and ROS (Graham 
1978). In line with this, protection of neuronal damage by MPP+ has been achieved in cell 
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cultures treated with antioxidants (Perry et al. 1985), and resistance to MPP+ neurotoxicity has 
been demonstrated in SOD transgenic mice (Cadet et al. 1995; Przedborski et al. 1992).  
 
Nitration and oxidative stress 
Immunohistochemical studies (Dehmer et al. 2000; Liberatore et al. 1999) show that iNOS up-
regulation occurs in microglia 24 hours after the administration of MPTP, an effect that lead to 
an increase in the production of NO and, subsequently, of OONO-. Both NO and OONO- may 
interfere with mitochondrial function (Cleeter et al. 1994; Radi et al. 1994), thus adding to the 
toxic effect of MPP+ on cellular energy supplies. Evidence for a role of NO in these effects 
comes from studies showing that inhibition of NOS can attenuate MPTP neurotoxicity in non-
human primates (Hantraye et al. 1996) and mice (Przedborski et al. 1996; Smith et al. 1994).  
An excitotoxic mechanism for MPTP neurotoxicity has also been proposed, based initially on the 
observation that intrastriatal administration of MPP+ to rats can lead to a marked increase in 
extracellular GLU and aspartate levels (Carboni et al. 1990). Subsequently, the neuroprotective 
effects of excitatory amino acid receptor antagonists have been described (Turski et al. 1991; 
Zuddas et al. 1992). Furthermore, overstimulation of GLU receptors can alter local Ca++ 
homeostasis, and Ca++ is known to up-regulate enzymes like phospholipase A2, nNOS and 
xanthine oxidase, all of which are found in mitochondria and can elevate ROS production, 
eventually promoting mitochondrial dysfunction. 
 
Neuroinflammation  
The idea that glia may participate in MPTP-induced neurotoxicity is supported by findings 
showing that toxins activate microglia and promote the production of toxic compounds, and that 
astroglia is the major site where MPTP is metabolized to MPP+.  
After the discovery of the presence of gliosis in post-mortem brains from MPTP-lesioned 
addicts, similar findings were later observed in the SNc of non-human primates (Barcia et al. 
2004; McGeer et al. 2003) and mice (Czlonkowska et al. 1996; Kohutnicka et al. 1998; 
Kurkowska-Jastrzebska et al. 1999). The inflammation discovered in humans and experimental 
animals exposed to MPTP may be related to activated microglial cells, that express inflammatory 
mediators such NO and cytokines (IL-1β and IL-6), as well as ROS, TNF-α, GLU, and 
arachidonic acid metabolites, which are toxic to dopaminergic neurons (Hanisch 2002). In line 
with this, an increase in both glial cells expressing iNOS and levels of proteins that contain nitro-
tyrosine have been detected in autoptic samples from the SNc of patients with idiopatic PD 
(Hunot et al. 1996). In this regard, Hirsch and Hunot (2000) suggested that MPTP acts directly 
on the induction of cytokines that activate iNOS, although elevation in striatal IL-1β and IL-6 
33 
content seems to differ between idiopatic PD and MPTP mouse model of PD. The study of Mogi 
and colleagues (1994) in the caudate nucleus, putamen and cerebral cortex of idiopatic PD 
patients reported an increase in both IL-1β and IL-6, compared with control subjects, but other 
studies in mice reported an increase of striatal IL-6 levels, and no increase in IL-1β levels (Kaku 
et al. 1999; Luo et al. 2004). Further supporting a role of activated microglia in MPTP-induced 
neurotoxicity in mice, Liberatore and colleagues (1999) have shown that microglial cells not 
only increase in number after MPTP injection, but also can flood dopaminergic neurons with 
large amounts of NO and OONO-. 
In contrast to the possible deleterious role of microglia, a neuroprotective role for activated 
astrocytes has been suggested in idiopathic PD as well as in MPTP-induced experimental PD. 
Astrocytes may reduce the cellular stress by metabolizing DA, since they express MAO type B 
and COMT (Ekblom et al. 1993; Huang et al. 2005). Additionally, astrocytes are capable to 
prevent NO-generated neurotoxicity by a GSH-dependent mechanism (Chen et al. 2004). 
 
 
 
Figure 4. Mechanism of MPTP toxicity. 
 
2.3 MPTP and the limbic system in humans and mice  
Cognitive impairment is one of the most common and important non-motor aspects of PD, and 
varies from mild deficits to severe dementia (Dubois and Pillo 1997; Lees and Smith 1983; 
Owen et al. 1992; Svenningsson et al. 2012). Mild cognitive impairment is most common in the 
early stages of the disease, as up to a third of patients may have cognitive deficits at the time of 
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their diagnosis (Foltynie et al. 2004). Nigrostriatal dysfunction alone is probably not sufficient 
for the development of cognitive deficits in PD patients, and it is interesting to remark that 
activated microglia have been observed not only in the SNc and putamen, where DA loss is 
prominent, but also in the hippocampus of PD patients (McGeer et al. 1988 and 2001; McGeer 
and McGeer 2004). As mentioned earlier, activated microglia produce a variety of inflammatory 
cytokines (Allan and Rothwell 2001), which have been implicated in cognitive deficits in PD 
(Menza et al. 2010; Wilson et al. 2002). In addition, supporting a link between IL and cognitive 
performance, it is noteworthy that IL-2 immunotherapy of cancer patients is associated with 
pronounced cognitive disturbances (Caraceni et al. 1993; Denicoff et al. 1987), particularly in 
tests involving spatial learning and memory (Caraceni et al. 1993). 
Data suggesting a link between neuroinflammation and cognitive deficits have also been 
obtained in mice, where MPTP treatment induces dopaminergic neurons loss in the SNc paired 
with a great inflammatory response (Frau et al. 2011; Miller et al. 2011) and cognitive deficits 
(Dluzen and Kreutzberg 1993; Deguil et al. 2010; Tanila et al. 1998). The increase of IL-6 in 
areas such as the hippocampus and hypothalamus induced by MPTP may be related to 
parkinsonian-like cognitive deficits (Wang et al. 2009), however, may be not the only 
responsible. Since the mechanism of cognitive deficits in PD has not been elucidated yet, the 
degree of striatal DA loss, the extent of neuroinflammation, as well as modifications in other 
brain areas related to cognitive processes may all potentially be involved and combine to elicit 
cognitive deficits observed in MPTP-treated mice. 
 
2.4 MPTP and the PFC in humans and experimental animals  
In idiopathic PD patients, abnormal cortical metabolic activity occurs in both the motor and non-
motor regions (Eidelberg et al. 1994; Huang et al. 2007; Ridding et al. 1995). An hypothesis is 
that such changes could index the non-motor symptoms of PD thought to precede the more 
classic motor manifestations, such as depression, cognitive deficits and apathy (Cooper et al. 
1991; Shen et al. 2013), and which involve brain areas, including the PFC, where was found a 
reduced DA content following treatment with dopaminergic neurotoxicant (Tadaiesky et al. 
2008). Supporting a role of PFC in MPTP-induced cognitive deficits in experimental animals, a 
study by Storvik and co-workers (2010) has shown that specific transcriptomic changes occurr in 
the PFC of parkinsonian MPTP-treated macaques, and that a large part of these changes may also 
be observed in human post-mortem samples from patients with neurodegenerative diseases, such 
as PD and Alzheimer disease, analysed by quantitative PCR. Similar results were obtained with a 
single intranasal infusion of MPTP in rats and mice, which produces progressive signs of PD 
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such as impairments in olfactory, cognitive, and motor functions, associated with a decrease in 
the levels of DA in the olfactory bulb, striatum, and PFC (Prediger et al. 2010). 
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Aims of the study 
 
On the basis of epidemiological studies showing a higher incidence of PD in amphetamine-
related drugs consumers, the present study evaluated in mice treated as adolescent with MDMA, 
and administered after MDMA washout with MPTP, the neuroinflammatory and neurotoxic 
effects in motor brain areas and the neuroinflammatory effects in non-motor brain areas. 
Moreover, cognitive deficits were evaluated by memory tasks.  
The first aim of this study was to assess whether administration of MDMA to late adolescent 
mice may facilitate the neuroinflammatory and neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP), in the nigrostriatal system of adult mice. Studies on the effects of 
amphetamine-related drugs in an experimental model of PD may, in fact, not only help to 
understand whether there is an increased risk of developing PD associated with the use of these 
substances during adolescence, but also clarify some of the mechanisms that promote the 
degeneration of DA neurons. 
To pursue this first aim, the following experiments were carried out: 
• Assessment of inflammatory response in SNc and striatum studied through 
immunohistochemical analysis of GFAP and CD11b, as markers of astroglia and 
microglia. 
• Assessment of dopaminergic neuronal damage in SNc and striatum studied by TH 
immunohistochemistry. 
The second aim of this study was to elucidate whether MDMA may amplify the 
neuroinflammatory effect elicited by MPTP in the hippocampus and in the mPFC. In the attempt 
to link neurochemical changes with behavioral modifications, this study investigated whether 
cognitive impairment took place in mice treated with MDMA, MPTP, and their combination. 
To pursue this second aim, the following experiments were carried out: 
• Assessment of inflammatory response in hippocampus and mPFC studied through 
immunohistochemical analysis of GFAP and CD11b. 
• Assessment of NOR task and spontaneous alternation behavior in a Y-maze, which were 
performed both throughout the MDMA treatment and after MPTP administration. 
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Materials and methods 
4.1 Animals 
Male C57BL/6J mice (Charles River, Calco, Italy) weighing 20–23 g at the beginning of the 
experiments, were used. Mice were maintained at constant temperature (21±1°C) under a 12-h 
light/dark cycle with food and water ad libitum. Experimental procedures were approved by the 
Ethical Committee of the University of Cagliari, in compliance with Italian guidelines for care 
and use of experimental animals (DL 116/92) and European Communities Council Directive 
(2010/63/EEC). Efforts were made to minimize the number of animals used and maximize 
humane treatment. 
 
4.2 Drugs 
MDMA was synthesized at the Department of Environmental and Life Sciences of the University 
of Cagliari (Frau et al. 2013). MPTP was purchased from Santa Cruz Biotechnology, CA, USA. 
MDMA was dissolved in saline, whereas MPTP was dissolved in distilled water. Both drugs 
were administered intraperitoneally (i.p.) in a volume of 10 ml/kg. 
 
4.3 Treatment 
Late adolescent mice (8 weeks old) were treated with either MDMA (10 mg/kg i.p.) or vehicle 
according to a 9-week administration schedule (Fig. 5). In detail, each mouse received two 
administrations a day, separated by a 4–6-hour interval, twice a week, on the second and fifth 
day of each week, for a total of 36 MDMA, or vehicle, administrations. Experimental groups 
were composed as follows: MDMA-treated mice, n=18-19; vehicle-treated mice n=17-18. 
During MDMA treatment, mice performance in the NOR was evaluated at the following time 
points: week 1, week 4, and week 9 and then re-assessed two weeks after MDMA 
discontinuation. NOR performance was always measured on the sixth day of the week. The same 
mice were also evaluated for spontaneous alternation behavior in a Y-maze, 24 h after NOR 
(seventh day of the week) at the same time points indicated above. Two weeks after MDMA 
discontinuation, mice (19 weeks old) were distributed into four groups and challenged with 
either MPTP (20 mg/kg, i.p.) or vehicle, once a day for 4 consecutive days. Experimental groups 
were composed as follows: vehicle+vehicle, vehicle+MPTP, MDMA+vehicle, MDMA+MPTP 
(n=5-10). Mice were evaluated again for their NOR performance and spontaneous alternation in 
a Y-maze, respectively after 24 or 48 hours from the last MPTP or vehicle injection. The day 
after the completion of behavioral experiments, mice were anesthetized with chloral hydrate, 
transcardially perfused with 4% paraformaldehyde in phosphate buffer (0.1 M, pH 7.4), and their 
brains were removed and processed for immunohistochemistry. 
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Figure 5. Experimental design. 
 
4.4 Immunohistochemistry  
For each mouse, three sections from: SNc (anterior–posterior: −2.92 mm to −3.52 mm from 
bregma); striatum (anterior–posterior: 1.34 mm to 0.74 mm from bregma); hippocampus 
(anterior–posterior: 1.46 mm to 1.82 mm from bregma) and mPFC (anterior–posterior: 2.22 mm 
to 1.78 mm from bregma), according to the atlas of Paxinos and Franklin (2008), were 
considered for each analysis.  
Coronal brain sections (50 µm thick) were cut on a vibratome. Free-floating sections of SNc, 
striatum, hippocampus and mPFC were incubated overnight with CD11b, GFAP or TH 
antibodies (monoclonal rat anti-CD11b, 1:1000, Serotec, Oxford, UK; monoclonal mouse anti-
GFAP, 1:400, Sigma, Milan, Italy; polyclonal rabbit anti-TH, 1:1000, Millipore, Milan, Italy). After 
incubation with primary antibodies, slices were incubate in proper biotinylated secondary 
antibodies (Vector, Peterborough, UK), and avidin-peroxidase protocol (ABC, Vector, 
Peterborough, UK) was applied for visualization, using 3,3’-diaminobenzidine (Sigma, Milan, 
Italy) as a chromogen. Sections were then mounted onto gelatine-coated slides to allow 
microscopy evaluation.  
 
Analysis of CD11b immunoreactivity 
Two portions of striatum (dorsolateral and ventromedial), two of SNc (lateral and medial), Cornu 
Ammonis regions of hippocampus (CA1, CA2 and CA3), and the whole prelimbic/infralimbic 
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area of mPFC were analyzed for both hemispheres. Images were digitized with a video camera 
(Pixelink® PL-A686, Ottawa, Canada), captured at ×20 real magnification in gray scale, and then 
evaluated with the Scion Image analysis software (Scion Corp. Frederick, MD, USA). A 
threshold, set above the mean value ± S.E.M. of the background, was applied for background 
correction. The area occupied by values above the threshold was automatically calculated inside 
each frame. No significant differences in CD11b levels were obtained between the two portions 
of SNc, the two portions of striatum or the three regions of the hippocampus, therefore the data 
obtained were pooled together. For each level of these areas, the obtained value was first 
normalized with respect to vehicle, and values from different levels were averaged thereafter. 
 
Analysis of GFAP immunoreactivity 
For the striatum, the hippocampus and the mPFC, GFAP analysis was performed similarly to 
what described for CD11b, whereas, for the SNc, the whole left and right area were analyzed. 
Images were captured and evaluated with the Pixelink® software. Absolute number of GFAP-
positive cells was obtained separately for each level within each brain area, and no significant 
differences in the number of GFAP-positive cells were observed among the two hemispheres of 
SNc, the two portions of striatum or among the three regions of the hippocampus, therefore the 
data obtained were pooled together. Thereafter, the number of cells × level from each mouse was 
normalized with respect to vehicle, and individual values from the levels were averaged to 
generate a mean value. 
 
Stereological counting of TH-positive neurons 
The total number (N) and density (D) of TH-positive neurons in SNc were measured 
stereologically on both hemispheres using a microscope (Leica, DMLB, Ballerup, Denmark) 
equipped with a projecting camera (Basler Vision Technologies, Ahrensburg, Germany) and a 
microscope stage connected to an xyz stepper (PRIOR ProScan) controlled by a computer 
equipped with new CAST Visiopharm software (Denmark).  
Systemic uniform, random sampling was used to choose sections for analysis. The SNc region 
was carefully outlined under lower magnification (×5) according to the atlas Paxinos and 
Franklin (2008). 
The number of labelled neurons was calculated under ×63 magnification using randomized 
meander sampling and optical dissector methods. The cut thickness of sections was 50 µm and 
the optical dissector height was 12 µm. The sampling area covered 20% of the region of interest. 
The counting frame (8183, 4 µm2) applied the exclusion and inclusion lines. In each sampled 
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area, the dissector position was adjusted. For further details see Frau et al. (2011) and Sterio 
(1984). 
 
Analysis of TH-positive fibers  
Images were digitized in gray scale, then TH-immunoreacted striata were captured at 20× real 
magnification in gray scale and evaluated using the image analysis software Scion Image. The 
average gray values from white matter were subtracted from each section to correct for 
background immunoreactivity.  
For each level of striatum, the obtained value was first normalized with respect to vehicle, and 
values from different levels were averaged thereafter. 
 
4.5 Memory tasks 
 
NOR task 
Evaluation of NOR performance is widely used for assessing non-spatial working memory in 
rodents (Ennaceur and Delacour 1988). NOR experiments were performed in a Plexiglas cage 
(length 25.5 cm, width 19 cm, height 14 cm) with the floor covered with sawdust. Objects to be 
discriminated were made of plastic, and differed as to their shape and color. Moreover, objects 
had no genuine significance, and had not been previously associated with either rewarding or 
aversive stimuli. Experimental procedure consisted of three phases: habituation (S0), acquisition 
(S1), and testing (S2). Habituation to the test cage (single 5 min trial) took place on the fifth day 
of the week during MDMA treatment, and on the fourth day during MPTP treatment, 6 hours 
after drug administration. Acquisition was performed the day after S0, by placing each mouse in 
the test cage together with two copies of the same object (familiar objects). Mice were left to 
freely explore the objects for 3 min. Testing phase took place 60 min after S1. Mice were 
exposed to a copy of the objects already presented in S1, plus a copy of an object that they had 
never experienced before (novel object).  
Objects exploration was defined as the mouse sniffing, gnawing or touching the objects with the 
nose, whereas sitting on and/or turning around the objects were not considered exploratory 
behaviors. To avoid the presence of olfactory cues, objects were thoroughly cleaned after each 
session. Moreover, the combination of objects (novel vs. familiar) and their respective locations 
in the cage (right vs. left) were counterbalanced, to prevent biased preferences for particular 
objects and/or locations. Mice performance was videotaped, and the following parameters were 
evaluated: total amount of time spent by each mouse in exploring the objects during S1 and S2, 
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and percentage of time spent exploring the novel object over the total amount of time spent in 
exploring both objects (novel and familiar) during S2 (Sawyer et al. 2012; Simola et al. 2008). 
 
Spontaneous alternation behavior in a Y-maze 
Evaluation of spontaneous alternation behavior in a Y-maze is widely utilized to investigate 
spatial short-term memory and general cognitive function in rodents (Hughes 2004; Maurice et 
al. 1994; Yamada et al, 1996). The apparatus used was made of black PVC, and had three equal 
arms (length 40 cm, width 11 cm, height 20.5 cm). Arms converged onto a central triangular 
area, and the maze had his floor covered with sawdust. To avoid the presence of olfactory cues, 
the maze was thoroughly cleaned and the sawdust was replaced in between each trial. Mice were 
individually placed in the central area, and left free to explore the whole apparatus for a single 8 
min trial, during which their performance was videotaped. Percentage of spontaneous alternation 
was calculated based on the sequence of arm entries, as reported elsewhere (Simola et al. 2008; 
Yamada et al. 1996). 
 
4.6 Statistics 
Statistical analysis was performed with Statistica for Windows (StatSoft, Tulsa, OK, USA). The 
statistical significance was assessed by Student’s t-test, one, or two-way analysis of variance 
(ANOVA), followed by Newman–Keuls post-hoc test when appropriate. Three animals were 
excluded from the analysis of behavioral tests, because they did not perform the tasks assigned. 
Significance was set at p<0.05. Results are expressed as mean±S.E.M. for every analysis 
performed.  
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Results 
 
5.1 MDMA increases the vulnerability of mice to neuroinflammation and neurotoxicity 
induced by MPTP in the SNc and striatum 
 
5.1.1 Immunohistochemistry  
 
CD11b immunoreactivity in SNc and striatum  
In vehicle+vehicle treated mice, resting microglia and very low levels of CD11b were observed, 
in both the SNc and the striatum. Similarly, mice exposed to chronic MDMA (10 mg/kg twice a 
day/twice a week) followed by vehicle administration did not show significant microglia 
activation, in both the SNc and the striatum. On the other hand, MPTP administration (20 mg/kg 
× 4 administrations) to vehicle-pretreated mice elicited an elevation in microglia in the SNc, 
compared to vehicle+vehicle, and a higher elevation in microglia in striatum, compared to 
vehicle+vehicle and MDMA+vehicle treated mice. Finally, MPTP administration to MDMA-
pretreated mice elicited a higher microglia activation in both the SNc and striatum, compared to 
all the other groups (Fig. 6).  
In the SNc, one-way ANOVA showed a significant effect of treatment (F3,19=4.82, p<0.01), and 
subsequent Newman-Keuls post-hoc test revealed that the levels of CD11b were higher in 
vehicle+MPTP mice compared with vehicle+vehicle treated mice. Moreover, MPTP 
administration in MDMA pretreated mice elicited a significantly higher microglia activation 
compared with all the other experimental groups (Fig.6A). 
In the striatum, one-way ANOVA showed a significant effect of treatment (F3,18=20.05, p<0.01), 
and subsequent Newman-Keuls post-hoc test revealed that the levels of CD11b were higher in 
vehicle+MPTP mice compared with vehicle+vehicle and MDMA+vehicle treated mice. 
Moreover, MPTP administration in MDMA pretreated mice elicited a significantly higher 
microglia activation compared with all the other experimental groups (Fig.6B). 
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Figure 6. Representative sections and histograms of the SNc (A) and striatum (B) 
immunostained for CD11b are shown. Experimental groups: vehicle+vehicle (SNc: n=8, 
striatum: n=6); MDMA+vehicle (SNc: n=5, striatum: n=6); vehicle+MPTP (n=5 both for the 
SNc and striatum); MDMA+MPTP (n=5 both for the SNc and striatum). Scale bar: 50 µm. 
*P<0.01, **P<0.001 vs vehicle+vehicle; #P<0.05, ##P<0.001 vs MDMA+vehicle; ^P<0.05; 
^^P<0.01 vs vehicle+MPTP, by the Newman–Keuls post-hoc test.  
 
GFAP immunoreactivity in SNc and striatum 
Similar to what observed for CD11b, vehicle+vehicle mice displayed few astroglial cells, which 
showed a highly branched morphology with tiny processes and a small body, in both the striatum 
and SNc. Mice exposed to chronic MDMA (10 mg/kg twice a day/twice a week) followed by 
vehicle administration did not show significant astroglia activation, in both the SNc and the 
striatum. On the other hand, MPTP administration (20 mg/kg × 4 administrations) to vehicle-
pretreated mice elicited an elevation in astroglia in both the SNc and striatum, compared to 
vehicle+vehicle and MDMA+vehicle treated mice. Finally, MPTP administration to MDMA-
pretreated mice elicited a higher astroglia activation in both the SNc and striatum, compared to 
all the other groups (Fig. 7).  
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In the SNc, one-way ANOVA showed a significant effect of treatment (F3,22=32.58, p<0.01), and 
subsequent Newman-Keuls post-hoc test revealed that the levels of GFAP were higher in 
vehicle+MPTP mice compared with vehicle+vehicle and MDMA+vehicle treated mice. 
Moreover, MPTP administration in MDMA pretreated mice elicited a significantly higher 
astroglia activation compared with all the other experimental groups (Fig.7A). 
In the striatum, one-way ANOVA showed a significant effect of treatment (F3,20=441.1, p<0.01), 
and subsequent Newman-Keuls post-hoc test revealed that the levels of GFAP were higher in 
vehicle+MPTP mice compared with vehicle+vehicle and MDMA+vehicle treated mice. 
Moreover, MPTP administration in MDMA pretreated mice elicited a significantly higher 
astroglia activation compared with all the other experimental groups (Fig. 7B). 
 
 
 
 
Figure 7. Representative sections and histograms of the SNc (A) and striatum (B) 
immunostained for GFAP are shown. Experimental groups: vehicle+vehicle (n=8 both for the 
SNc and striatum); MDMA+vehicle (SNc: n=8, striatum: n=6); vehicle+MPTP (n=5 both for 
SNc and striatum); MDMA+MPTP (n=5 both for the SNc and striatum). Scale bar: 50 µm. 
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*P<0.005, **P<0.001 vs vehicle+vehicle; #P<0.005, ##P<0.001 vs MDMA+vehicle; ^^P<0.001 
vs vehicle+MPTP, by the Newman–Keuls post-hoc test.  
 
TH immunoreactivity in SNc and striatum 
In vehicle+vehicle treated mice were not observed any decrease in both N and D of TH-positive 
neurons in the SNc, and in TH-positive fibers in the striatum.On the other hand, mice exposed to 
chronic MDMA (10 mg/kg twice a day/twice a week) followed by vehicle administration show a 
significant decrease in both the N and the D of TH-positive neurons in the SNc, whereas no 
significant decreased was found in the striatum. MPTP administration (20 mg/kg × 4 
administrations) to vehicle-pretreated mice elicited a decrease in both the N and the D of TH-
positive neurons in the SNc, and in TH-positive fibers in the striatum, compared to 
vehicle+vehicle treated mice. Finally, MPTP administration to MDMA-pretreated mice elicited a 
higher decrease in both the N and the D of TH-positive neurons in the SNc, and in TH-positive 
fibers in the striatum, compared to all the other groups (Fig. 8).  
In the SNc, one-way ANOVA showed a significant effect of treatment (N: F3,15=21.09, p<0.01; 
D: F3,15=21.35, p<0.01). Subsequent Newman-Keuls post-hoc test revealed that the N and the D 
of TH-positive neurons of MDMA+vehicle treated mice were lower, compared to 
vehicle+vehicle treated mice. Moreover, as previously reported (Frau et al. 2011), administration 
of MPTP (20 mg/kg i.p. ×4 administrations) in vehicle-pretreated mice induced a decrease in 
both the N and the D values compared with vehicle+vehicle treated mice. Interestingly, chronic 
administration of MDMA followed by MPTP administration determined a further decrease in 
both N and D values compared with all other experimental groups (Fig. 8A). Examination of the 
VTA, did not show any decrease in TH-positive neurons (data not shown). 
In the striatum, one-way ANOVA showed a significant effect of treatment (F3,23=10.52, p<0.01). 
Subsequent Newman-Keuls post-hoc test revealed that administration of MPTP (20 mg/kg i.p. 
×4 administrations) in vehicle-pretreated mice induced a decrease in the TH-positive fibers 
compared with vehicle+vehicle treated mice. Interestingly, chronic administration of MDMA 
followed by MPTP administration determined a further decrease in the TH-positive fibers 
compared with all other experimental groups (Fig.8B). TH fiber loss was homogeneous along the 
rostrocaudal axis of the striatum. 
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Figure 8. Representative sections and histograms of the SNc (A) and striatum (B) 
immunostained for TH are shown. Experimental groups: vehicle+vehicle (SNc: n=7; striatum: 
n=8); MDMA+vehicle (SNc: n=5; striatum: n=9); vehicle+MPTP (n=5 both for SNc and 
striatum); MDMA+MPTP (n=5 both for SNc and striatum). Scale bar: 50 µm for SNc; 200 µm 
for striatum. 
*P<0.05, **P<0.001 vs vehicle+vehicle; #P<0.01, ##P<0.005 vs MDMA+vehicle; ^P<0.05 vs 
vehicle+MPTP, by the Newman–Keuls post-hoc test. 
 
5.2 MDMA increases the vulnerability of mice to the neuroinflammation induced by MPTP 
in the hippocampus and mPFC and is associated with cognitive deficits 
 
5.2.1 Immunohistochemistry  
 
CD11b immunoreactivity in hippocampus and mPFC  
Vehicle+vehicle mice showed low levels of CD11b in both the hippocampus and mPFC. 
Similarly, mice exposed to chronic MDMA (10 mg/kg twice a day/twice a week) followed by 
vehicle administration did not show significant microglia activation. On the other hand, MPTP 
administration (20 mg/kg × 4 administrations) to vehicle-pretreated mice elicited an elevation in 
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microglia in the hippocampus compared to vehicle+vehicle and MDMA+vehicle mice. Finally, 
MPTP administration to MDMA-pretreated mice elicited a higher microglia stimulation in both 
the hippocampus and mPFC, compared to all the other groups (Fig. 9). 
In the hippocampus, one-way ANOVA showed a significant effect of treatment (F3,25=9.19, 
p<0.01), and subsequent Newman-Keuls post-hoc test revealed that the levels of CD11b were 
higher in vehicle+MPTP mice compared with vehicle+vehicle mice and MDMA+vehicle mice. 
Interestingly, chronic administration of MDMA followed by MPTP administration determined a 
further increase in the levels of CD11b, compared with both vehicle+vehicle and 
MDMA+vehicle mice (Fig. 9A).  
In the mPFC, one-way ANOVA indicated a significant effect of treatment (F3,16=6.89, p<0.01), 
and subsequent Newman-Keuls post-hoc test showed that MDMA+MPTP mice exhibited CD11b 
levels significantly higher than those observed in all the other experimental groups (Fig. 9B). 
 
 
 
Figure 9. Representative sections and histograms of the hippocampus (A) and mPFC (B) 
immunostained for CD11b are shown. Experimental groups: vehicle+vehicle (hippocampus: 
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n=9, mPFC: n=5); MDMA+vehicle (hippocampus: n=5, mPFC: n=5); vehicle+MPTP 
(hippocampus: n=7, mPFC: n=5); MDMA+MPTP (hippocampus: n=8, mPFC: n=5). Scale bar: 
50 µm. *P<0.05, **P<0.001 vs vehicle+vehicle; #P<0.05, ##P<0.005 vs MDMA+vehicle; 
^^P<0.001 vs vehicle+MPTP, by Newman–Keuls post-hoc test. 
 
GFAP immunoreactivity in hippocampus and mPFC 
Vehicle+vehicle mice displayed astroglial cells with highly branched morphology, tiny processes 
and a small body in both the hippocampus and mPFC. Similarly, mice exposed to chronic 
MDMA (10 mg/kg twice a day/twice a week) followed by vehicle administration did not show a 
significant astroglia activation. On the other hand, MPTP administration (20 mg/kg × 4 
administrations) to vehicle-pretreated mice elicited an elevation in astroglia in the hippocampus 
compared to vehicle+vehicle mice. Moreover, MPTP administration to MDMA-pretreated mice 
elicited a higher elevation in microglia in the hippocampus and mPFC compared to all the other 
groups (Fig. 10). 
In the hippocampus, one-way ANOVA revealed a significant effect of treatment (F3,34=9.42, 
p<0.01), and subsequent Newman-Keuls post-hoc test showed that the number of GFAP-positive 
cells was higher in vehicle+MPTP mice compared with vehicle+vehicle mice. Interestingly, 
chronic administration of MDMA followed by MPTP administration determined a further 
increase in GFAP levels, compared with all the other experimental groups (Fig. 10A).  
In the mPFC, one-way ANOVA showed a significant effect of treatment (F3,16=10.09, p<0.01), 
and subsequent Newman-Keuls post-hoc test revealed that the number of GFAP-positive cells 
was higher in MDMA+MPTP mice, compared with all the other experimental groups (Fig. 10B). 
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Figure 10. Representative sections and histograms of the hippocampus (A) and mPFC (B) 
immunostained for GFAP are shown. Experimental groups: vehicle+vehicle (hippocampus: n=9, 
mPFC: n=5); MDMA+vehicle (hippocampus: n=10, mPFC: n=5); vehicle+MPTP (hippocampus: 
n=9, mPFC: n=5); MDMA+MPTP (hippocampus: n=10, mPFC: n=5). Scale bar: 50 µm. 
*P<0.05; **P<0.001 vs vehicle+vehicle; ##P<0.005 vs MDMA+vehicle; ^P<0.05; ^^P<0.01 vs 
vehicle+MPTP, by Newman–Keuls post-hoc test. 
 
5.2.2 Memory tasks 
 
NOR task 
No significant modifications in NOR performance were observed during chronic administration 
of MDMA (10 mg/kg, i.p., twice a day/twice a week), compared with vehicle administration. 
Two-way ANOVA revealed no significant effect of chronic treatment (F1,29=0.04, p=0.84), no 
significant effect of time (F2,58=1.09, p=0.34), and no significant chronic treatment × time 
interaction (F2,58=0.51, p=0.34). However, when re-evaluated two weeks after treatment 
discontinuation, MDMA-treated mice showed an impairment in NOR performance compared 
with vehicle-treated mice, as shown by t-test (df =32 , t =4.10 , p < 0.01) (Fig. 11A).  
When NOR performance was re-evaluated in the same mice 24 hours after the last injection of 
MPTP (20 mg/kg × 4 administrations), one-way ANOVA revealed a significant effect of 
treatment (F1,31=10.3, p=0.01). Subsequent Newman-Keuls post-hoc indicated that both 
MDMA+vehicle and vehicle+MPTP mice had an impaired NOR performance, compared with 
vehicle+vehicle mice, and that MDMA+MPTP mice had a poorer NOR performance compared 
with all the other experimental groups (Fig. 11B). In all the NOR experiments performed, no 
significant differences in the total amount of time spent exploring the objects during either S1 or 
S2 were observed among the various experimental groups (data not shown).  
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Figure 11. Representative histograms of NOR performance measured on week 1, week 4, and 
week 9 and then re-assessed two weeks after MDMA discontinuation (A). Representative 
histograms of NOR performance measured 24 hours after the last injection of MPTP (B). 
Experimental groups: MDMA (n=18); vehicle (n=18); vehicle+vehicle (n=9); MDMA+vehicle 
(n=10); vehicle+MPTP (n=9); MDMA+MPTP (n=8).  
**P<0.005 vs vehicle+vehicle; #P<0.05 vs MDMA+vehicle; ^P<0.05 vs vehicle+MPTP, by t-
test, or Newman–Keuls post-hoc test.  
 
Spontaneous alternation behavior in a Y-maze 
No significant changes in spontaneous alternation behavior were observed during chronic 
treatment with MDMA (10 mg/kg, i.p., twice a day/twice a week), compared with chronic 
vehicle administration (Fig. 12A). Two-way ANOVA revealed no significant effect of repeated 
treatment (F1,29=1.8, p=0.19), no significant effect of time (F2,58=1.24, p=0.30), and no 
significant  repeated treatment × time interaction (F2,58=1.2, p=0.31). Similar results were 
observed when mice were re-evaluated two weeks after MDMA discontinuation, as shown by 
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Student’s t-test (df=32, t =0.33, p=0.74). Finally, administration of MPTP (20 mg/kg × 4 
administrations) did not affect spontaneous alternation behavior measured 48 hours after the last 
MPTP injection, as shown by one-way ANOVA  (F1,31=0.08, p=0.97) (Fig. 12B). 
 
 
 
Figure 12. Representative histograms of spontaneous alternation behavior measured on week 1, 
week 4, and week 9 and then re-assessed two weeks after MDMA discontinuation (A). 
Representative histograms of spontaneous alternation behavior performance measured 24 hours 
after the last injection of MPTP (B). Experimental groups: MDMA (n=19); vehicle (n=17); 
vehicle+vehicle (n=8); MDMA+vehicle (n=10); vehicle+MPTP (n=9); MDMA+MPTP (n=9).  
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Discussion 
 
In this work of thesis, late adolescent mice were treated as adolescent with MDMA, and 
administered as adults, after MDMA washout, with MPTP, a neurotoxin relevant for humans as it 
can induce a syndrome that reproduces the features of PD (Langston and Ballard 1983; Langston 
et al. 1983 and 1999), in order to study whether MDMA pre-exposure could modify the 
vulnerability to the noxious effects of MPTP. The results of this study demonstrate that the 
neuroinflammation in the nigrostriatal, limbic and cortical systems, as well as the neurotoxicity 
in the nigrostriatal system, elicited by MPTP, was exacerbated by chronic administration of 
MDMA to mice during adolescence. Moreover, MDMA administration during adolescence 
induces cognitive impairment, and amplified the detrimental effects of MPTP on cognitive 
performance measured at adulthood. 
The study of how MDMA modulates the toxic effects of other substances appears a “hot topic” 
in neuropharmacology and neurotoxicology because this drug is largely consumed by 
adolescents (Strote et al. 2002), and adolescence is a critical period for the development of the 
brain (Casey et al. 2000). The adolescent brain appears particularly vulnerable to the long-term 
noxious effects of exogenous substances, including drugs of abuse (Cadoni et al. 2013; Daza-
Losada et al. 2009). It has been demonstrated, in rats, that almost all drugs causing drug 
addiction increase the release of DA in the mesolimbic pathway (Pierce and Kumaresan 2006), 
and it has been demonstrated that amphetamine administration in adolescent rats induces a 
prominent sensitization of DA release, whereas no change was found in adult rats (Laviola et al. 
2001). Therefore, it is becoming increasingly clear that MDMA should be regarded as harmful 
not only because its use may have implications for drug dependence (Fernandez-Serrano et al. 
2011; Smirnov et al. 2013), but also because MDMA use could function as a “primer” for later 
brain insults.  
Besides showing detrimental effects of MDMA itself, studies in experimental animals have 
shown that this substance may amplify the neuroinflammation and neurotoxicity elicited by other 
psychoactive/toxic substances, eventually leading to the exacerbation of neuronal damage. The 
potentiation of MPTP-mediated neuroinflammation in mice pretreated with MDMA during 
adolescence appeared very marked in striatum and mPFC, lower in SNc and hippocampus, 
involving both microglia and astroglia. It should be noted that MDMA alone did not appear to 
produce an increase in neuroinflammation in any brain areas evaluated. In this regard, it has to 
be considered that in the present study immunohistochemical evaluation of microglia and 
astroglia was performed three weeks after the last MDMA administration, and therefore it is 
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feasible that the acute neuroinflammatory effects of MDMA may have faded over time. 
Moreover, it has to be take into account the differences in doses and protocols of MDMA 
administration between the present and previous studies (Frau et al. 2013; Granado et al. 2008a 
and 2011; Khairnar et al. 2009). 
It is noteworthy that MPTP alone elicited both astrogliosis and microgliosis in the SNc, striatum 
and hippocampus, compared with vehicle+vehicle treated mice. At variance with these results, 
neither MDMA nor MPTP alone significantly stimulated both astrogliosis and microgliosis in the 
mPFC. This latter finding deserves consideration, since it suggests that the neurochemical 
modifications induced by repeated exposure to MDMA, even if subtle, may prime the brain for 
the effects of later noxious stimuli. In addition, MPTP administration in MDMA pretreated mice 
significantly stimulates astrogliosis, but not microgliosis, in the hippocampus, compared with 
MPTP alone. These results are confirmed by previous evidences in rodents studies reporting 
neuroinflammatory effects of MPTP in the SNc, striatum (Czlonkowska et al. 1996; Kohutnicka 
et al. 1998; Kurkowska-Jastrzebska et al. 1999; Kurosaki et al. 2003), and hippocampus 
(Kokovay and Cunningham 2005; Sy et al. 2010; Wang et al. 2009). The increased microgliosis 
and astrogliosis in hippocampus could be explained by the presence of a very high density of 
binding sites for MPP+ in this region (Del Zompo et al. 1992). As suggested by Thomas and co-
workers (2004), the amphetamine-related drugs associated with DA or 5-HT nerve terminal 
damage also cause microglial activation, whereas non-neurotoxic amphetamine-related drugs do 
not have this effect.  
MPTP administration in mice chronically pretreated during late adolescence with MDMA 
induced higher dopaminergic neuron degeneration than in MPTP or MDMA alone treated mice. 
Since, in these mice, the degree of neuronal degeneration induced by MPTP appears additive to 
that induced by MDMA, we speculate that dopaminergic degeneration produced by MDMA may 
create the basis for a degeneration which could reach the critical threshold to induce PD in 
presence of environmental toxins. Moreover, mice chronically treated with MDMA showed 
reduced N and the D of TH-positive neurons in the SNc three weeks after the interruption of 
MDMA treatment. This result, in line with previous reports showing that acute repeated MDMA 
administration produces dopaminergic neuron degeneration (Granado et al. 2008a and 2011), 
adds the important indication that also sporadic, but prolonged treatment of mice with this drug 
is toxic to dopaminergic neurons. Therefore, MDMA, like other recognized amphetamine-related 
drugs, such as methamphetamine (Albers et al. 1996; Sinchai et al. 2011), increases 
dopaminergic neuron vulnerability even when administered at low/medium doses and in an 
irregular way. Regarding the reduction in N and the D of TH-positive neurons in the SNc but not 
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in TH-positive fibers in striatum it can be hypothesized, as previously suggested (Rosenblad et 
al. 1999), that partial DA lesion might be associated to compensatory sprouting in the striatum. 
As mentioned in the introduction, MDMA and MPTP have several common mechanisms able to 
induce toxicity and this could underlie the exacerbation of MPTP-mediated neuroinflammatory 
and neurotoxic effects observed in MDMA pretreated mice. MDMA has been reported to inhibit 
the CYP2D6 (O’Mathùna et al. 2008), which has been shown to convert MPTP into non-toxic 
metabolites (Herraiz et al. 2006; Mann and Tyndale 2010). In addition, it is possible that 
prolonged exposure to MDMA result in an elevation of intracellular oxidative stress, due to 
several mechanisms, that would eventually render neurons more sensitive to the effects of MPTP, 
which acts itself by promoting the generation of ROS (Cleeter et al. 1992; Sriram et al. 1997). 
Thus, it has been demonstrated that MDMA, as MPTP, can inhibit mitochondrial complex I in 
mice (Nicklas et al. 1985; Puerta et al, 2010; Suzuki et al. 1990), leading to mitochondria 
inactivation and oxidizing macromolecules such as lipids, DNA, and proteins. Moreover, 
MDMA, could amplify oxidative stress also by promoting the release of DA (Cadoni et al. 
2005), which can undergo auto-oxidation, and in turn generate free radicals and ROS (Marchitti 
et al. 2007; Siraki and O'Brien 2002; Stokes et al. 1999), eventually leading to the exacerbation 
of neuroinflammatory and neurotoxic phenomenons triggered by a later noxious insult. This 
latter mechanism could be particularly relevant to the results of this study, as it might justify why 
MDMA pre-exposure was associated with a more marked exacerbation of MPTP-
neuroinflammation in the striatum and mPFC, and neurotoxicity in SNc, which are highly 
enriched with dopaminergic terminals and neurons (Bentivoglio and Morelli 2005), than in the 
hippocampus, where dopaminergic innervation is less dense (Bentivoglio and Morelli, 2005; 
Milner and Bacon 1989).  
In addition to neuroinflammatory and neurotoxic changes, mice treated with MDMA during 
adolescence displayed a persistent impairment in NOR performance after treatment 
discontinuation, and MDMA pretreatment was found to further aggravate cognitive impairment 
induced by MPTP. These results appear of great relevance since, despite the ever-increasing use 
of MDMA in humans, scarce information is available on the long-term effects on cognition 
elicited by the consumption of this drug during adolescence. Importantly, the impairment in 
NOR performance observed in this study appears clearly attributable to deficits in cognitive 
function. In fact, no differences were found between MDMA- and vehicle-treated mice as for the 
total amount of time spent in object exploration during both S1 and S2. This indicates that the 
regimen of MDMA used in this study is devoid of non-specific effects on object exploration. 
Moreover, MDMA seemed not to alter the ability of mice to discriminate between different 
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objects. In fact, mice could recognize novel objects at different time points during the MDMA 
treatment, but eventually loses this ability when re-evaluated at two weeks after treatment 
discontinuation, which would suggest the onset of progressive and long-term toxicity of MDMA. 
Striatum, hippocampus and mPFC have been shown to regulate item recognition in rodents 
(Cropley et al. 2006; Dalley et al. 2004; Eichenbaum et al. 1996; Landau et al. 2009; Ragozzino 
et al. 1999; Squire 1992). Therefore, the impairment in NOR performance observed here is likely 
attributable to the neuroinflammatory effect caused by MDMA and MPTP in these areas. 
Remarkably, a support to the existence of a causal link between neuroinflammation and 
cognitive impairment comes from previous studies which have employed the systemical or 
intrahippocampal injection of lipopolysaccharide (LPS) in rodents. Thus, LPS has been shown 
not only to stimulate the expression of inflammation-related molecules, including GFAP, iNOS, 
cycloxygenase (COX)-2, IL-6 and IL-1β (Herber et al. 2006; Jain et al. 2002; Pang et al. 2006; 
Sparkman et al. 2006) but also to engender cognitive impairment. Furthermore, METH, the 
abuse of which in humans is often associated with neurocognitive impairment (Nestor et al. 
2011; North et al. 2013), causes an inflammatory response characterized by an upregulation of 
GFAP and CD11b levels,TNF-α, and TNF-receptor 1 protein levels (Gonçalves et al. 2010) in 
mice.  
Interestingly, the cognitive impairment was narrowed to NOR, whilst no deficits were detectable 
in spontaneous alternation behavior. This lack of effect could be observed both during MDMA 
treatment and following MPTP administration, and no exacerbation of MPTP effects was present 
in MDMA-treated mice. These results could be explained in the light of previous studies that 
have shown how spontaneous alternation behavior may be relatively resistant to noxious brain 
insults that impair NOR performance, suggesting a different sensitivity of these two tasks to 
neuronal damage (Moriguchi et al. 2012; Simola et al. 2008). Moreover, it is interesting to 
consider that MPTP has been demonstrated to scarcely affect alternation behavior in mice (Tanila 
et al. 1998), which could justify the lack of an impairment in spontaneous alternation behavior in 
mice challenged with MPTP.  
The present study, encompassing both neurochemical and behavioral findings, may significantly 
contribute to the elucidation of the interactions between MDMA and substances which are toxic 
for the brain, and appear also of potential relevance for humans. Several clinical and preclinical 
studies recognize that PD has multiple origins, from genes to toxins and several concomitant 
factors may contribute to its development (Marsden and Olanow 1998). Since one of the 
possibilities taken into account in PD pathology is the use of amphetamine-related drugs, the 
results of the present work of thesis support the hypothesis these substances might be part of the 
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multiple factors that lead to dopaminergic neuron degeneration and microglial activation 
associated with PD. Thus, a major conclusion that can be drawn from the present study is that the 
detrimental effects of MDMA, even if subtle, appear to be long-lasting, since they could be 
detected after treatment discontinuation. By showing an exacerbation of MPTP effects in several 
brain areas as SNc, striatum, hippocampus and mPFC of mice pre-exposed to MDMA, this study 
indicates that noxious MDMA-MPTP interactions are widespread in the brain. Moreover, it was 
observed that the abuse of MDMA creates the basis for a worsening in cognitive function, in 
agreement to data from several studies in adult MDMA consumers (Bolla et al. 1998; Brown et 
al. 2010; Fox et al. 2001; Morgan 2000; Parrott and Laskey 1998).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
57 
Conclusions 
 
In conclusion, by demonstrating that mice repeatedly treated with MDMA during adolescence 
display an exacerbation in neuroinflammation, neurotoxicity and cognitive impairment induced 
by MPTP, a dopaminergic toxin relevant to humans, the present results underline the importance 
of exploring the long-term effects of amphetamine-related drugs, to clarify their potential as risk 
factors for the development of neurological and behavioral problems later in life. 
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